0001144204-16-100593.txt : 20160511 0001144204-16-100593.hdr.sgml : 20160511 20160510194606 ACCESSION NUMBER: 0001144204-16-100593 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160511 DATE AS OF CHANGE: 20160510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NORTHWEST BIOTHERAPEUTICS INC CENTRAL INDEX KEY: 0001072379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943306718 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35737 FILM NUMBER: 161637419 BUSINESS ADDRESS: STREET 1: 4800 MONTGOMERY LANE STREET 2: SUITE 800 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: (240) 497-9024 MAIL ADDRESS: STREET 1: 4800 MONTGOMERY LANE STREET 2: SUITE 800 CITY: BETHESDA STATE: MD ZIP: 20814 10-Q 1 v439072_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______to _______

Commission File Number: 001-35737

NORTHWEST BIOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or Other Jurisdiction of Incorporation or

Organization)

94-3306718

(I.R.S. Employer Identification No.)

4800 Montgomery Lane, Suite 800, Bethesda, MD 20814

(Address of principal executive offices) (Zip Code)

(240) 497-9024

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer x	Non-accelerated filer ¨	Smaller reporting company ¨
(do not check if a smaller reporting company)

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ¨ No x

As of May 6, 2016, the total number of shares of common stock, par value $0.001 per share, outstanding was 101,740,440.

NORTHWEST BIOTHERAPEUTICS, INC.

FORM 10-Q

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION		3

Item 1.	Condensed Consolidated Interim Financial Statements (Unaudited)

	Condensed Consolidated Balance Sheets as of March 31, 2016 and December 31, 2015	3

	Condensed Consolidated Statements of Operations for the three months ended March 31, 2016 and 2015	4

	Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2016 and 2015	5

	Condensed Consolidated Statement of Stockholders’ Equity (Deficit) for the three months ended March 31, 2016	6

	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2016 and 2015	7

	Notes to Condensed Consolidated Financial Statements	9

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	25

Item 4.	Controls and Procedures	25

PART II - OTHER INFORMATION		26

Item 1.	Legal Proceedings	26

Item 1A.	Risk Factors	27

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28

Item 3.	Defaults Upon Senior Securities	29

Item 4.	Mine Safety Disclosures	29

Item 5.	Other Information	29

Item 6.	Exhibits	29

SIGNATURES		30

PART I - FINANCIAL INFORMATION

NORTHWEST BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(in thousands, except share and per share amounts)

	March 31,			December 31,
	2016			2015
ASSETS
Current assets:
Cash and cash equivalents	$	11,688		$	21,813
Restricted cash - interest payments held in escrow		746			886
Prepaid expenses and other current assets		1,065			1,402
Total current assets		13,499			24,101

Non-current assets:
Property, plant and equipment, net		48,360			46,157
Restricted cash - interest payments held in escrow, net of current portion		214			349
Other assets		153			190
Total non-current assets		48,727			46,696

Total assets	$	62,226		$	70,797

COMMITMENTS AND CONTINGENCIES

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable	$	8,726		$	11,721
Accounts payable to related party		6,366			5,455
Accrued expenses (includes related party of $12 and $11 as of March 31, 2016 and December 31, 2015, respectively)		1,189			1,309
Convertible notes, net (includes related party note of $50 as of March 31, 2016 and December 31, 2015)		185			185
Note payable - in dispute		934			934
Mortgage loan (net of deferred financing cost of $321 and $468 as of March 31, 2016 and December 31, 2015, respectively)		10,950			11,144
Environmental remediation liability		6,200			6,200
Shares payable to related party		8,799			-
Derivative liability		14,457			27,982
Total current liabilities		57,806			64,930

Non-current liabilities:
Convertible note (net of deferred financing cost of $387 and $457 as of March 31, 2016 and December 31, 2015, respectively)		10,613			10,543
Total non-current liabilities		10,613			10,543

Total liabilities		68,419			75,473

Commitments and Contingencies

Stockholders' equity (deficit):
Preferred stock ($0.001 par value); 40,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively		-			-
Common stock ($0.001 par value); 450,000,000 shares authorized; 101,740,440 and 95,858,087 shares issued and outstanding as of March 31, 2016 and December 31, 2014, respectively		102			96
Additional paid-in capital		634,696			630,613
Accumulated deficit		(641,368	)		(635,262	)
Accumulated other comprehensive gain (loss)		377			(123	)
Total stockholders' equity (deficit)		(6,193	)		(4,676	)
Total liabilities and stockholders' equity (deficit)	$	62,226		$	70,797

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NORTHWEST BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share amounts)

	For the three months ended
	March 31,
	2016			2015
Revenues:
Research grant and other	$	236		$	194
Total revenues		236			194
Operating costs and expenses:
Research and development		13,440			19,625
General and administrative		4,275			3,400
Total operating costs and expenses		17,715			23,025
Loss from operations		(17,479	)		(22,831	)
Other income (expense):
Change in fair value of derivative liability		13,525			(23,158	)
Interest expense		(718	)		(793	)
Foreign currency transaction (loss) gain		(1,434	)		349
Net loss	$	(6,106	)	$	(46,433	)

Net loss per share applicable to common stockholders - basic and diluted	$	(0.06	)	$	(0.67	)

Weighted average shares used in computing basic and diluted loss per share		97,688			69,406

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NORTHWEST BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

(in thousands)

	For the three months ended
	March 31,
	2016			2015
Net loss	$	(6,106	)	$	(46,433	)
Other comprehensive income (loss)
Foreign currency translation adjustment		500			(68	)
Total comprehensive loss	$	(5,606	)	$	(46,501	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NORTHWEST BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

(in thousands)

	Common Stock				Additional Paid-in			Accumulated			Cumulative Translation				Total Stockholders
	Shares		Par value		Capital			Deficit			Adjustment				Equity (Deficit)
Balance January 1, 2016		95,858	$	96	$	630,613		$	(635,262	)	$	(123	)	$	(4,676	)
Issuance of common stock and warrants for cash in a registered direct offering		5,882		6		9,994			-			-			10,000
Offering cost related to registered direct offering		-		-		(756	)		-			-			(756	)
Shares payment due to Cognate BioServices		-		-		(5,155	)		-			-			(5,155	)
Net loss		-		-		-			(6,106	)		-			(6,106	)
Cumulative translation adjustment		-		-		-			-			500			500
Balance at March 31, 2016		101,740	$	102	$	634,696		$	(641,368	)	$	377		$	(6,193	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NORTHWEST BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

	For the three months ended
	March 31,
	2016			2015
Cash Flows from Operating Activities:
Net Loss	$	(6,106	)	$	(46,433	)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization		13			3
Amortization of deferred financing cost		209			234
Change in fair value of derivatives		(13,525	)		23,158
Accrued interest converted to common stock		-			(349	)
Stock issued to Cognate BioServices under Cognate Agreements		3,644			6,359
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		337			(279	)
Accounts payable and accrued expenses		(3,116	)		(378	)
Related party accounts payable and accrued expenses		912			103
Other non-current assets		37			-
Net cash used in operating activities		(17,595	)		(17,582	)
Cash Flows from Investing Activities:
Purchase of property, plant and equipment		(2,683	)		(1,133	)
Funding of escrow - convertible notes		275			-
Net cash used in investing activities		(2,408	)		(1,133	)
Cash Flows from Financing Activities:
Proceeds from mortgage loan		-			4,997
Deferred offering cost related to mortgage loan		-			(138	)
Proceeds from issuance of common stock and warrants in a registered direct offering		10,000			-
Offering cost related to registered direct offering		(756	)		-
Proceeds from exercise of warrants		-			3,651
Net cash provided by financing activities		9,244			8,510
Effect of exchange rate changes on cash and cash equivalents		634			(15	)
Net decrease in cash and cash equivalents		(10,125	)		(10,220	)

Cash and cash equivalents at beginning of year		21,813			13,390
Cash and cash equivalents at end of year	$	11,688		$	3,170

Supplemental disclosure of cash flow information
Interest payments on mortgage loan	$	(334	)	$	(307	)
Interest payments on senior convertible notes	$	(275	)	$	(428	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NORTHWEST BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - CONTINUED

(Unaudited)

(in thousands)

	For the three months ended
	March 31,
	2016		2015
Supplemental schedule of non-cash investing and financing activities:
Accrued Exit Fee incurred from mortgage loan	$	-	$	50
Cashless warrant exercise on warrant liability	$	-	$	520
Increase in accounts payable related to UK property	$	-	$	257
Interest payment on convertible note from escrow	$	-	$	428
Redeemable security settlement	$	-	$	299

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Organization and Description of Business and Recent Developments

Northwest Biotherapeutics, Inc. and its subsidiaries NW Bio Europe S.A.R.L, NW Bio Gmbh and Aracaris Capital, Ltd. (collectively, the “Company”, “we”, “us” and “our”) were organized to discover and develop innovative immunotherapies for cancer.

The Company’s platform technology, DCVax®, is currently being tested for the treatment of certain types of cancers through clinical trials in the United States and Europe that are in various phases.

2. Liquidity and Financial Condition

For the three months ended March 31, 2016 and 2015, we recognized a net loss of $6.1 million and a net loss of $46.4 million, respectively.

During the three months ended March 31, 2016, the Company used approximately $17.6 million of cash in its operating activities. These cash outflows included substantial amounts of accrued costs relating to periods of higher activity and expenditures in the Company’s Phase III clinical trial which have subsequently been reduced, and included substantial amounts of legal costs which the Company anticipates may be subject to reimbursement under the Company’s insurance, with further legal expenses going forward being covered by insurance directly. The Company had cash and cash equivalents of $11.7 million and a working capital deficiency (cash and non-cash liabilities combined) of approximately $44.3 million at March 31, 2016 (with $14.5 million of the $44.3 million deficit comprised of non-cash derivative liabilities and $6.2 million comprised of projected potential future liability for future environmental costs). The Company owes an aggregate of $6.4 million of trade liabilities and convertible notes to related parties.

Because of recurring operating losses, net operating cash flow deficits, and an accumulated deficit there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might become necessary should the Company be able to continue as a going concern.

3. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated.

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of March 31, 2016, condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015, condensed consolidated statements of comprehensive loss for the three months ended March 31, 2016 and 2015, condensed consolidated statement of stockholders’ equity (deficit) for the three months ended March 31, 2016, and the condensed consolidated statements of cash flows for the three months ended March 31, 2016 and 2015 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months ended March 31, 2016 are not necessarily indicative of results to be expected for the year ending December 31, 2016 or for any future interim period. The condensed consolidated balance sheet at March 31, 2016 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2015, and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on March 16, 2016.

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Use of Estimates

In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, valuing environmental liabilities, estimating the fair value of equity instruments recorded as derivative liabilities, and estimating the useful lives of depreciable assets and whether impairment charges may apply.

Warrant Liability

The Company accounts for certain common stock warrants outstanding as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company's statements of operations. The fair value of the warrants issued by the Company in connection the Conversion Transaction has been estimated using a Monte Carlo simulation.

Environmental Remediation Liabilities

The Company records environmental remediation liabilities for properties acquired. The environmental remediation liabilities are initially recorded at fair value. The liability is reduced for actual costs incurred in connection with the clean-up activities for each property. Upon completion of the clean-up, the environmental remediation liability is adjusted to equal the fair value of the remaining operation, maintenance and monitoring activities to be performed for the property. The amount of the liability resulting from the completion of the clean-up, if any, would be included in other income (expense). As of March 31, 2016, the Company estimated that the total environmental remediation costs associated with the purchase of the UK Facility will be approximately $6.2 million. This is a projected potential future cost. No such environmental costs have been incurred to date and none are currently pending. Contamination clean-up costs that improve the property from its original acquisition state will be capitalized as part of the property’s overall development costs. The Company engaged a third party specialist to conduct certain surveys of the condition of the property which included, among other things, a preliminary analysis of potential environmental remediation exposures. The Company determined, based on information contained in the specialist’s report, that it would be required to estimate the fair value of an unconditional obligation to remediate specific ground contamination at an estimated fair value of approximately $6.2 million. The Company computed the fair value of this obligation using a probability weighted approach that measures the likelihood of the following two potential outcomes: (i) a higher probability requirement of erecting a protective barrier around the affected area at an estimated cost of approximately $4.5 million, and (ii) a lower probability requirement of having to excavate the affected area at an estimated cost of approximately $32.0 million. The Company’s estimate is preliminary and therefore subject to change as further studies are conducted, and as additional facts come to the Company’s attention. Environmental remediation efforts are complex, technical and subject to various uncertainties. Accordingly, it is at least reasonably possible that any changes in the Company’s estimate could materially differ from the management’s preliminary assessment discussed herein.

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Foreign Currency Translation and Transactions

The Company has operations in Germany, the United Kingdom and Canada, in addition to the U.S. Assets and liabilities are translated into U.S. dollars using end of period exchange rates and revenues and expenses are translated into U.S. dollars using weighted average rates. Foreign currency translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) within stockholders’ equity (deficit).

During the three months ended March 31, 2016, the Company recorded $0.5 million of foreign currency translation gain primarily due to the strengthening of the U.S. dollar relative to the euro and British pound sterling.

Foreign currency transaction losses are recognized in the Consolidated Statements of Operations as incurred.

Comprehensive Loss

The Company reports comprehensive loss and its components in its consolidated financial statements. Comprehensive loss consists of net loss and foreign currency translation adjustments, affecting stockholders’ equity (deficit) that, under U.S, GAAP, is excluded from net loss.

Research and Development Costs

Research and development costs are charged to operations as incurred and consist primarily of clinical trial costs, related party manufacturing costs, consulting costs, contract research and development costs, clinical site costs and compensation costs.

For the three months ended March 31, 2016 and 2015, the Company recognized research and development costs of $13.4 million and $19.6 million, respectively.

Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2015 Annual Report.

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Recent Accounting Pronouncements

In January 2016, FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 requires equity investments to be measured at fair value with changes in fair value recognized in net income; simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment; eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets on the balance sheet or the accompanying notes to the financial statements; and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. ASU 2016-01 will be effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact that ASU 2016-01 will have on its condensed consolidated financial statements and related disclosures.

In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842) which supersedes FASB ASC Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard will be effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company is currently evaluating the impact that ASU 2016-02 will have on its condensed consolidated financial statements and related disclosures.

In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). The amendment is to simplify several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, the amendments in ASU 2016-09 are effective for interim and annual reporting periods beginning after December 15, 2016. The Company is currently assessing the impact of ASU 2016-09 on its condensed consolidated financial statements and related disclosures.

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

4. Fair Value Measurements

The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of March 31, 2016 and December 31, 2015 (in thousands):

Fair value measured at March 31, 2016

Quoted prices in active

Significant other

Significant

Fair value at

markets

observable inputs

unobservable inputs

March 31, 2016

(Level 1)

(Level 2)

(Level 3)

Derivative liability

14,457

Fair value measured at December 31, 2015

Quoted prices in active

Significant other

Significant

Fair value at

markets

observable inputs

unobservable inputs

December 31, 2015

(Level 1)

(Level 2)

(Level 3)

Derivative liability

27,982

There were no transfers between Level 1, 2 or 3 during the three-month period ended March 31, 2016.

The following table presents changes in Level 3 liabilities measured at fair value for the three-month period ended March 31, 2016. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (in thousands).

	Warrant
	Liability
Balance - January 1, 2016	$	27,982
Change in fair value		(13,525	)
Balance – March 31, 2016	$	14,457

The Company’s warrant liabilities are measured at fair value using the Monte Carlo simulation valuation methodology. A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy for the three months ended March 31, 2016 is as follows:

Date of valuation	January 1, 2016			March 31, 2016
Strike price	$	3.49		$	2.38
Volatility (annual)		86.9	%		85.9	%
Risk-free rate		1.3	%		0.9	%
Contractual term (years)		3.1			3.0
Dividend yield (per share)		0	%		0	%

The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

5. Property, Plant and Equipment

Property and equipment consist of the following at March 31, 2016 and December 31, 2015 (in thousands):

	March 31,			December 31,
	2016			2015
Leasehold improvements	$	69		$	69
Office furniture and equipment		25			25
Computer equipment and software		602			597
UK property acquisition, construction and estimated environmental liability		47,893			45,681

		48,589			46,373
Less: accumulated depreciation		(229	)		(216	)
	$	48,360		$	46,157

Depreciation expense was approximately $13,000 and $3,000 for the three months ended March 31, 2016 and 2015.

6. Notes Payable

2014 Convertible Senior Notes

The Company has Convertible Senior Notes of $10.6 million, net of $0.4 million deferred offering cost as of March 31, 2016 with an interest rate of 5% and conversion price of $6.60. The Company has remaining $1.0 million in escrowed interest payments, which is sufficient to fund, when due, the total aggregate amount of the six scheduled semi-annual interest payments during the remaining term of the notes, excluding additional interest, if any.

The following table shows the details of interest expenses related to 2014 Convertible Senior Notes for the three months ended March 31, 2016 and 2015, respectively (in thousands):

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

	For the three months ended
	March 31,
	2016		2015
Contractual interest	$	137	$	216
Amortization of debt issuance costs		70		105
Total interest expense on the convertible senior notes	$	207	$	321

Mortgage Loan

The Company has two 12% mortgage loans that are secured by the UK facility with principal of $11.3 million, net of deferred financing costs of $0.3 million. $4.7 million of the mortgage loans are due in August 2016 and the remainder in November 2016.

Interest expense was approximately $0.4 million and $0.3 million for the three months ended March 31, 2016 and 2015, respectively, which includes $0.1 million amortization of deferred offering financing costs in both periods.

Other Notes Payable

Notes payable consist of the following at March 31, 2016 and December 31, 2015 (in thousands):

	March 31,		December 31,
	2016		2015
Notes payable – current
12% unsecured originally due July 2011 - in dispute (1)	$	934	$	934
		934		934
Convertible notes payable, net - current
6% unsecured (2)		135		135
		135		135
Note payable
6% due on demand (3)		50		50
		50		50

Total notes payable, net	$	1,119	$	1,119

(1) This $0.934 million note, which was originally due in July 2011 is currently under dispute with the creditor as to the validity of the note payable balance, which the Company believes has already been paid in full and is not outstanding.

(2) This $0.135 million note as of March 31, 2016 consists of two separate 6% notes in the amounts of $0.110 million and $0.025 million. In regard to the $0.110 million note, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the $0.025 million note, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents.

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

(3) This $0.050 million demand note as of March 31, 2016 is held by an officer of the Company. The holder has made no demand for payment, but reserves the right to make a demand at any time.

7. Net Loss per Share Applicable to Common Stockholders

Options, warrants, and convertible debt outstanding were all considered anti-dilutive for the three months ended March 31, 2016, and 2015, due to net losses.

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented (in thousands):

	For the three months ended
	March 31,
	2016		2015
Common stock options		1,551		1,551
Common stock warrants - equity treatment		26,876		15,830
Common stock warrants - liability treatment		15,839		12,500
Convertible notes and accrued interest		1,743		2,797
Potentially dilutive securities		46,009		32,678

8. Related Party Transactions

Cognate BioServices, Inc.

Cognate Expenses and Accounts Payable

At March 31, 2016 and December 31, 2015, the Company owed Cognate $6.4 million and $5.5 million, respectively, for unpaid invoices for manufacturing and related services.

Overall, for the three months ended March 31, 2016 and 2015, the Company incurred research and development costs (cash and non-cash) related to Cognate BioServices of $11.2 million and $14.7 million, respectively, relating to the DCVax-L and DCVax-Direct programs, product and process development work and preparations for upcoming Phase II trials.

Share Based Payments

The Company recorded $5.2 million of income and $6.4 million of expense for the three-month period ended March 31, 2016 or 2015, respectively, for stock based payment expense to Cognate for the applicable pro rata portion of the ongoing 3-year vesting of the one-time initiation payments under Manufacturing and Services Agreement that were entered into in January 2014. The fair value calculation of these shares was determined using the market price for tradable shares.

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Shares payable to related party – most favored nation provision

The shares and warrants previously issued to Cognate in partial payment of invoices for manufacturing services continue to be under a 3-year lock-up, which has been in place since January 2014, preventing Cognate from selling them. If the Company enters into a transaction with other investors or creditors during this lock-up period on more favorable terms than Cognate received, the Company has an ongoing obligation to conform the terms of Cognate’s shares and warrants to the same terms as the other investors or creditors, under a most favored nation provision.

On March 3, 2016, the Company entered into a financing under which it sold 5.9 million common shares and 12.1 million Series A, B and C warrants to unrelated investors on terms more favorable than the existing terms of Cognate’s shares. The sale of common shares had an effective price of $1.7, which triggered a most favored nation obligation which would result in an obligation to issue 6.0 million shares to Cognate. However, these shares have not been issued, and the Company is in active negotiations with Cognate seeking to modify these arrangements.

While these negotiations are ongoing, the Company has accrued $8.8 million to represent shares payable to related parties on the condensed consolidated balance sheet based upon the closing stock price as of March 31, 2016 to recognize the contractual provision of the most favored nation clause.

9. Stockholders’ Equity (Deficit)

Common Stock Issuances

First Quarter 2016

In addition, the Company granted the Purchasers a sixty (60) day overallotment option in the form of Series B Warrants to purchase an additional 5,882,353 shares of Common Stock at an exercise price of $3.00 per share (the “Series B Warrants”). The Series B Warrants was exercisable immediately and was to expire within sixty (60) days. However, on May 2, 2016, the Company and the investors agreed to extend this warrant exercise period by twenty-one (21) days, from May 2 to May 23, 2016. The Company and the Purchasers consummated the purchase and sale of the Securities on March 3, 2016 (the “Closing”) and the Company raised gross proceeds of $10 million and net proceeds of approximately $9.2 million, after deducting placement agent fees, attorneys’ fees and other expenses. Subsequent to the reporting period, the Series B Warrants were extended an additional twenty-one (21) days to May 23, 2016.

In a concurrent private placement, each Purchaser will also receive Series C Warrants (the “Series C Warrants”) to purchase up to 2,941,177 shares of Common Stock. The Series C Warrants vest and become exercisable only if, and to the extent that, the Series B Warrants held by such Purchaser are exercised. The Series C warrants will be issuable and exercisable for one-half share of Common Stock per each Series B Warrant exercised. The Series C Warrants have an exercise price of $4.00 per share, shall be exercisable on the six-month anniversary of issuance and will expire five years thereafter.

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

In connection with the Offering and the concurrent private placement, the Company engaged H.C. Wainwright & Co., LLC (the “Placement Agent”) to act as its exclusive placement agent. The Company agreed to pay the Placement Agent a cash placement fee equal to 7% of the aggregate purchase price for the common stock sold in the registered offering. The Placement Agent will also receive Common Stock purchase warrants (the “Compensation Warrants”) to purchase up to 294,118 shares of Common Stock, or 5% of the aggregate number of shares of common Stock sold in the registered offering, at an exercise price of $2.125, or 125% of the public offering price per share in the registered offering, which are exercisable six months following issuance and terminate on February 29, 2021.

Stock Purchase Warrants

The following is a summary of warrant activity for the three months ended March 31, 2016 (in thousands, except per share data):

	Number of			Weighted Average
	Warrants			Exercise Price
Outstanding as of December 31, 2015		27,267,441		$	4.40
Warrants granted in a registered direct offering		12,058,825			3.04
Additional warrants owed to Cognate as part of reset		3,405,671			1.70
Warrants expired and cancelled		(16,791	)		11.86
Outstanding as of March 31, 2016		42,715,146		$	3.53

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

10. Contingencies

Derivative and Class Action Litigation

In 2014, as previously reported, the Company received demand letters from three purported individual shareholders seeking to inspect our corporate books and records pursuant to Section 220 of the Delaware General Corporation Law. The demand letters were all substantially similar, and claimed that their purpose is to investigate possible mismanagement and breaches of fiduciary duty by the Company’s directors and officers. They requested a range of documents. On November 13, 2014, one of the purported shareholders filed a complaint in the Delaware Court of Chancery seeking to enforce her books and records demand. The Company reached negotiated agreements and provided limited records, under confidentiality agreements. On July 16, 2015, the parties filed, and the court entered, a stipulation dismissing the case.

On June 19, 2015, two of the purported shareholders filed a complaint purportedly suing on behalf of a class of similarly situated shareholders and derivatively on behalf of the Company in the Delaware Court of Chancery. The lawsuit names Cognate BioServices, Inc., Toucan Partners, Toucan Capital Fund III, our CEO Linda Powers and the Company’s Board of Directors as defendants, and names the Company as a “nominal defendant” with respect to the derivative claims. The complaint generally objects to certain transactions between the Company and Cognate and the Toucan entities, in which Cognate and the Toucan entities provided services and financing to the Company, or agreed to conversion of debts owed to them by the Company into equity. The complaint seeks unspecified monetary relief for the Company and the plaintiffs, and various forms of equitable relief, including disgorgement of allegedly improper benefits, rescission of the challenged transactions, and an order forbidding similar transactions in the future. On September 1, 2015, the Company and other named defendants filed motions to dismiss. In response, the plaintiffs filed an amended complaint on November 6, 2015. The Company and the other named defendants filed motions to dismiss plaintiffs’ amended complaint on January 19, 2016. The plaintiffs filed an answering brief in opposition to the motion to dismiss on April 4, 2016. The Company intends to continue to vigorously defend the case.

On November 19, 2015, a third purported shareholder who had sought corporate books and records filed a complaint in the U.S. District Court for the District of Maryland, claiming to sue derivatively on behalf of the Company. The complaint names the Company’s Board of Directors, Toucan Capital Fund III, L.P., Toucan General II, LLC, Toucan Partners, LLC, and Cognate as defendants, and names the Company as a nominal defendant. The complaint claims that the plaintiff made a demand on the Company’s Board of Directors to commence an action against the Company’s directors and its CEO and that the plaintiff commenced the derivative action after not receiving a response to the demand letter within an allegedly “sufficient time.” The complaint further claims that the Company purportedly overcompensated Cognate and Toucan for certain services and loans in payments of stock, and that the Company’s CEO, Ms. Powers, benefited from these transactions with Cognate and Toucan, which she allegedly owns or controls. The complaint asserts that the alleged overpayments unjustly enriched Ms. Powers, Toucan, and Cognate. The Complaint also claims that the Company’s directors breached their fiduciary duties of loyalty and good faith to the Company by authorizing the payments to Cognate. Finally, the complaint claims that Ms. Powers, Cognate, and Toucan aided and abetted the directors’ breaches of fiduciary duties by causing the board to enter into the agreements with Cognate. The plaintiff seeks an award of unspecified damages to the Company and seeks equitable remedies, including disgorgement by Ms. Powers, Toucan, and Cognate of the allegedly improper benefits received as a result of the disputed transactions. The plaintiff also seeks costs and disbursements associated with bringing suit, including attorneys’ fees and expert fees. On February 2, 2016, plaintiff and defendants filed a joint motion to stay the proceedings pending an investigation by a special committee of the Company’s Board of Directors into the allegations asserted in the demand letter and underlying the lawsuit.

Class Action Securities Litigation

On August 26, 2015, a purported shareholder of the Company filed a putative class action complaint in the U.S. District Court for the District of Maryland. The lawsuit names the Company and Ms. Powers as defendants. On December 14, 2015, the court appointed two lead plaintiffs. The Lead Plaintiffs filed an amended complaint on February 12, 2016, purportedly on behalf of all of those who purchased common stock in NW Bio between January 13, 2014 and August 21, 2015. The amended complaint generally claims that the defendants violated Section 10(b) and Section 20(a) of the Securities Exchange Act of 1934 by making misleading statements and/or omissions on a variety of subjects, including the status and results of the Company’s DCVax trials. The amended complaint seeks unspecified damages, attorneys’ fees, and costs. The Company and Ms. Powers filed a motion to dismiss plaintiffs’ amended complaint on April 12, 2016. The Company intends to vigorously defend the case.

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Shareholder Books and Record Demand

On December 7, 2015, the Company received a letter on behalf of shareholders demanding to inspect certain corporate books and records pursuant to Section 220 of the Delaware General Corporation Law. The demand letter claimed that its purpose was to investigate: (1) allegedly improper transactions, misconduct, and mismanagement by directors and an officer of the Company; (2) the possible breach of fiduciary duty by certain directors and officers of the Company; and (3) the independence and disinterestedness of the Company’s board, to determine whether a pre-suit demand would be necessary before commencing any derivative action on behalf of the Company. The Company has appointed a special committee of its Board of Directors consisting of independent and disinterested directors to investigate the allegations set forth in the demand letter, as well as the allegations asserted in the litigation summarized above. The Company also is in ongoing discussions with the shareholders demanding corporate books and records.

11. Subsequent Events

The Company intends to take the appropriate steps to address the issues raised by the Nasdaq Staff as quickly as possible and is already in discussions with the Nasdaq Staff about two approaches to remediation. The Company intends to submit a remediation plan to Nasdaq promptly for its approval.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and the notes to those statements included with this report. In addition to historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words “believe,” “expect,” “intend,” “anticipate,” and similar expressions are used to identify forward-looking statements, but some forward-looking statements are expressed differently. Many factors could affect our actual results, including those factors described under “Risk Factors” in our Form 10-K for the year ended December 31, 2015 and in Part II Item 1A of this report. These factors, among others, could cause results to differ materially from those presently anticipated by us. You should not place undue reliance on these forward-looking statements.

Overview

We are a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and, through a proprietary batch manufacturing process, on a cost-effective basis, initially in the United States, Canada and Europe.

We have developed a platform technology, DCVax®, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The DCVax technology is expected to be applicable to all solid tumor cancers, and is embodied in several distinct product lines. One of the product lines (DCVax®-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax®-Direct) is designed for all solid tumor cancers which are considered inoperable and cannot be surgically removed. We believe the broad applicability of DCVax to many cancers provides multiple opportunities for commercialization and partnering.

Our DCVax platform technology involves dendritic cells, the master cells of the immune system, and is designed to reinvigorate and educate the immune system to attack cancers. The dendritic cells are able to mobilize the overall immune system, including T cells, B cells and antibodies, natural killer cells and many others. Such mobilization of the overall immune system provides a broader attack on the cancer than mobilizing just a particular component, such as T cells alone, or a particular antibody alone. Likewise, our DCVax technology is designed to attack the full set of biomarkers, or antigens, on a patient’s cancer, rather than just a particular selected target or several targets. Clinical experience indicates that when just one or a few biomarkers on a cancer are targeted by a drug or other treatment, sooner or later the cancer usually develops a way around that drug, and the drug stops working. We believe that mobilizing the overall immune system, and targeting the full set of biomarkers on the patient’s cancer, contributes to the effectiveness of DCVax.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect our reported amounts of assets, liabilities, revenues and expenses.

On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and stock-based compensation. We based our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results may differ from these estimates.

Our critical accounting policies and significant estimates are detailed in our Annual Report on Form 10-K for the year ended December 31, 2015. Our critical accounting policies and significant estimates have not changed substantially from those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2015.

Results of Operations

Operating costs:

Operating costs and expenses consist primarily of research and development expenses, including clinical trial expenses which increase when we are actively participating in clinical trials and are especially high when we are in a large ongoing international Phase III trial (as we now are), as well as preparing for multiple Phase II trials. Such costs have increased and will continue to increase as we expand and accelerate these programs, and bring on additional clinical trial programs and additional intellectual property development, and general and administrative expenses. Such expenses will also increase as we undertake preparations for eventual commercialization, which involves extensive work for process optimization, validation and scale-up. The associated administrative expenses also increase as such operating activities grow.

Research and development expense was $13.4 million for the three months ended March 31, 2016 versus $19.6 million for the three months ended March 31, 2015.

Our operating costs include ongoing development work relating to our DCVax products and their manufacturing, such as the development, testing and optimization of different product preparations and methods, the design, engineering, sourcing, production, testing, modification and validation of manufacturing automation systems, disposable sets to be used with the manufacturing automation systems, and manufacturing processes, product ingredients, product release assays, and other matters, as well as development of standard operating procedures (SOPs), batch production records, and other necessary materials.

Our operating costs also include the costs of expansion of our clinical trial programs including the Phase III trial in the US, UK, Germany and Canada (with DCVax-L for brain cancer), early access programs in Europe, and preparations for multiple Phase II trials. The preparation costs include product and process development, upfront payments to the clinical trial sites and the CROs managing the trials and other service providers, and legal, regulatory and expert expenses related to regulatory approvals, institutional approvals and clinical trial agreements with each site, database development, training of medical and other site personnel, trial supplies and other. Additional substantial costs relate to the expansion of manufacturing facilities and capacity, in both the US and Europe.

Research and development:

Discovery and preclinical research and development expenses include costs for external technical and regulatory advisers, scientific or medical personnel and others, costs of laboratory supplies and equipment used in research and development projects, travel, regulatory compliance, and expenditures for preclinical and clinical trial operation and management when we are actively engaged in clinical trials.

Because we are a pre-revenue company, we do not allocate research and development costs on a project basis. We adopted this policy, in part, due to the unreasonable cost burden associated with accounting at such a level of detail and our limited number of financial and personnel resources.

General and administrative:

General and administrative expenses include both cash and non-cash measures. The non-cash expenses include stock-based compensation and depreciation. The cash expenses include administrative personnel related salary and benefit expenses, cost of facilities, insurance and travel, property and equipment. The cash expenses also include large amounts of legal fees and related expenses, and substantial intellectual property costs.

Three Months Ended March 31, 2016 and 2015

For the three months ended March 31, 2016 and 2015, we recognized a net loss of $6.1 million and a net loss of $46.4 million, respectively. For the period ended March 31, 2016, the Company recorded additional income of $13.5 million related to the change in fair value of derivative liability. For the period ended March 31, 2015, the Company recorded a $23.2 million expense related to the change in fair value of derivative liability.

Research and Development Expense

Research and development expense was $13.4 million for the three months ended March 31, 2016 versus $19.6 million for the three months ended March 31, 2015. The decrease was primarily due to decreased non-cash manufacturing and services costs as described below.

For the three months ended March 31, 2016 and 2015, we made cash payments for the two periods, respectively, of approximately $5.2 million, and $8.2 million to Cognate. At March 31, 2016 and 2015, we owed Cognate $6.4 million and $5.5 million, respectively, for unpaid invoices for DCVax-L and DCVax-Direct programs, product and process development work and preparations for upcoming Phase II trials.

For the three months ended March 31, 2016 and 2015, we incurred non-cash equity based benefit and expense (restricted common stock and warrants) for the applicable pro rata portion of the ongoing vesting (in equal monthly installments over 3 years) of the one-time initiation payments of shares and warrants under the four agreements the Company entered into with Cognate in January 2014. The Company recorded $5.2 million of income and $6.4 million expense for the three months ended March 31, 2016 and 2015. The income in March 2016 was due to the drop in share price from December 31, 2015. The fair value calculation of these shares was determined using the market price for tradable shares; however the shares issued to Cognate were unregistered non-tradable shares subject to multiple restrictions including multi-year vesting and multi-year lock-up. The ongoing installments also included lock-up warrants (for a 3-year lock-up of Cognate shares) and most favored nation warrants.

General and Administrative Expense

General and administrative expense was $4.3 million (cash and non-cash expenses combined) for the three months ended March 31, 2016 versus $3.4 million for the three months ended March 31, 2015. The increase in general and administrative expenses can be attributed mainly to the increase in legal expenses.

Change in fair value of derivatives

During the three months ended March 31, 2016 and 2015 we recognized a non-cash gain of $13.5 million and a non-cash loss of $23.2 million, respectively. The change in the fair value of the derivative liability during the 1^st quarter of 2016 was due to a decrease in our stock price compared to the prior quarter, issued to Cognate in connection with the extinguishment of accounts payable

Interest Expense

Interest expense (including non-cash elements such as amortization of debt discount and debt issuance cost) $0.7 million and $0.8 million for the three months ended March 31, 2016 and 2015, respectively. The decrease is due to the reduction in outstanding debt in 2015.

Liquidity and Capital Resources

We have experienced recurring losses from operations. During the three months ended March 31, 2016 and 2015, net cash outflows from operations were $17.6 million for both periods.

At March 31, 2016, current assets totaled $13.5 million, compared to $24.1 million at December 31, 2015. Current assets less current liabilities produces working capital deficit (cash and non-cash liabilities combined) in the amount of $44.3 million at March 31, 2016 (with $14.5 million of the $44.3 million deficit comprised of non-cash derivative liabilities and $6.2 million comprised of an estimated liability for future environmental costs), compared to a deficit of $40.8 million at December 31, 2015, as described above.

Operating Activities

During the three months ended March 31, 2016 and 2015, net cash outflows from operations were $17.6 million for both periods.

Investing Activities

During the three months ended March 31, 2016 and 2015, we used $2.4 million and $1.1 million to capitalize costs related to the UK facility and UK facility purchase, respectively.

Financing Activities

During the three months ended March 31, 2016 and 2015, our financing activities provided net proceeds after expenses of $9.2 million and $8.5 million, respectively.

Our financial statements indicate there is substantial doubt about our ability to continue as a going concern as we are dependent on our ability to obtain ongoing financing and ultimately to generate sufficient cash flow to meet our obligations on a timely basis. We can give no assurance that our plans and efforts to achieve the above steps will be successful.

Other factors affecting our ongoing funding requirements include the number of staff we employ, the number of sites and number of patients still undergoing treatment in our Phase III brain cancer trial, the costs of further product and process development work relating to our DCVax products, the costs of preparations for multiple Phase II trials, the costs of expansion of manufacturing, the cost of pursuing our Hospital Exemption program and potential reimbursements in Germany, and unanticipated developments. The extent of resources available to us will determine which programs can move forward and at what pace.

Off-Balance Sheet Arrangements

Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Market risk represents the risk of loss that may result from the change in value of financial instruments due to fluctuations in its market price. Market risk is inherent in all financial instruments. Market risk may be exacerbated in times of trading illiquidity when market participants refrain from transacting in normal quantities and/or at normal bid-offer spreads. Our exposure to market risk is directly related to derivatives, debt and equity linked instruments related to our financing activities.

Our assets and liabilities are overwhelmingly denominated in U.S. dollars. We do not use foreign currency contracts or other derivative instruments to manage changes in currency rates. We do not now, nor do we plan to, use derivative financial instruments for speculative or trading purposes. However, these circumstances might change.

The primary quantifiable market risk associated with our financial instruments is sensitivity to changes in interest rates. Interest rate risk represents the potential loss from adverse changes in market interest rates. We use an interest rate sensitivity simulation to assess our interest rate risk exposure. For purposes of presenting the possible earnings effect of a hypothetical, adverse change in interest rates over the 12-month period from our reporting date, we assume that all interest rate sensitive financial instruments will be impacted by a hypothetical, immediate 100 basis point increase in interest rates as of the beginning of the period. The sensitivity is based upon the hypothetical assumption that all relevant types of interest rates that affect our results would increase instantaneously, simultaneously and to the same degree. We do not believe that our cash and equivalents have significant risk of default or illiquidity.

The sensitivity analyses of the interest rate sensitive financial instruments are hypothetical and should be used with caution. Changes in fair value based on a 1% or 2% variation in an estimate generally cannot be extrapolated because the relationship of the change in the estimate to the change in fair value may not be linear. Also, the effect of a variation in a particular estimate on the fair value of financial instruments is calculated independent of changes in any other estimate; in practice, changes in one factor may result in changes in another factor, which might magnify or counteract the sensitivities. In addition, the sensitivity analyses do not consider any action that we may take to mitigate the impact of any adverse changes in the key estimates.

Based on our analysis, as of March 31, 2016, the effect of a 100+/- basis point change in interest rates on the value of our financial instruments and the resultant effect on our net loss are considered immaterial.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Since 2012, our Company’s finance and accounting functions have been performed by an external firm on a contract services basis. This firm specializes in providing financing and accounting functions for biotech companies, and the founders and senior managers are highly experienced former partners of national accounting firms. Together with this external firm, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended.

Based on the evaluation of our disclosure controls and procedures, our principal executive, financial and accounting officer concluded that during the period covered by this report, our Company’s processes for internally reporting material information in a systematic manner to allow for timely filing of material information were improving compared with prior periods, but were not effective, due to inherent limitations from being a small company and insufficient personnel for segregation of duties, and there remain material weaknesses in our oversight over the financial reporting that contribute to the weaknesses in our disclosure controls and procedures. We have been working together with the external firm who performs the Company’s finance and accounting functions to address the weaknesses and enable increased segregation of duties and oversight, as described below.

Changes in Internal Control over Financial Reporting

We have been taking steps to remedy the weaknesses identified above, which continue to exist as of the end of the period covered by this report. Specifically, we are working with both counsel and consultants to address the weaknesses, and we have expanded the personnel resources allocated to our Company’s work, and the activities performed for our Company, by the external firm. We have recruited additional personnel, and we are in the process of recruiting further personnel, to enable increased segregation of duties and increased oversight. We plan to continue taking steps to improve our internal control system and to address remaining deficiencies, but the timing of such steps is uncertain and our ability to retain or attract qualified individuals to undertake these functions is also uncertain. Aside from these changes, there has been no change in our internal controls over financial reporting that occurred during the fiscal quarter ended March 31, 2016, that has materially affected, or is reasonably expected to materially affect, our internal controls over financial reporting.

Part II - Other Information

Item 1. Legal Proceedings

Derivative and Class Action Litigation

On June 19, 2015, two of the purported shareholders filed a complaint purportedly suing on behalf of a class of similarly situated shareholders and derivatively on behalf of the Company in the Delaware Court of Chancery. The lawsuit names Cognate BioServices, Inc., Toucan Partners, Toucan Capital Fund III, our CEO Linda Powers and the Company's Board of Directors as defendants, and names the Company as a "nominal defendant" with respect to the derivative claims. The complaint generally objects to certain transactions between the Company and Cognate and the Toucan entities, in which Cognate and the Toucan entities provided services and financing to the Company, or agreed to conversion of debts owed to them by the Company into equity. The complaint seeks unspecified monetary relief for the Company and the plaintiffs, and various forms of equitable relief, including disgorgement of allegedly improper benefits, rescission of the challenged transactions, and an order forbidding similar transactions in the future. On September 1, 2015, the Company and other named defendants filed motions to dismiss. In response, the plaintiffs filed an amended complaint on November 6, 2015. The Company and the other named defendants filed motions to dismiss plaintiffs' amended complaint on January 19, 2016. The plaintiffs filed an answering brief in opposition to the motion to dismiss on April 4, 2016. The Company intends to continue to vigorously defend the case

Class Action Securities Litigation

Shareholder Books and Record Demand

Item 1A. Risk Factors

Other than the following additional risk factor, the risk factors described in our most recent Annual Report on Form 10-K and other filings continue to apply as described therein:

If we fail to comply with NASDAQ listing rules, or remedy non-compliance, we could be subject to adverse action by NASDAQ

As the Company previously reported on Form 8-K, on April 26, 2016, the Company received a letter (the “Letter”) from the staff of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Staff had reviewed certain stock issuances by the Company to Cognate BioServices, Inc. (“Cognate”), and had determined that those issuances did not comply with Nasdaq Rules 5635(c) and (d). When a listed company fails to be in compliance with the listing rules of Nasdaq, there is a range of potential actions which may follow. The Nasdaq Staff and the company may negotiate and agree upon a remediation plan, or the Nasdaq Staff could issue a letter of reprimand, or the Nasdaq Staff could initiate a process to delist the company’s common shares. The Company is currently in discussions with Nasdaq about potential approaches to remedy the non-compliance with these rules and the Company intends to submit a remediation plan to Nasdaq promptly for its approval. However, there can be no assurance as to whether our plan will be accepted by Nasdaq or whether we will be able to reach agreement with Nasdaq on a remediation plan. If Nasdaq were to issue a letter of reprimand or initiate delisting proceedings against us, it could have a material adverse effect on the trading price and liquidity of our common stock.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On February 29, 2016, the Company entered into a Securities Purchase Agreement (the “Agreement”) with certain institutional investors (the “Purchasers”), for a registered direct offering (the “Offering”) of 5,882,353 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at the purchase price of $1.70 per share, and Series A Warrants (the “Series A Warrants”) to purchase an additional 2,941,177 shares of Common Stock at an exercise price of $2.25 per share. The Series A Warrants will become exercisable on the six month anniversary of issuance and expire five years thereafter. In addition, the Company granted the Purchasers a sixty (60) day overallotment option in the form of Series B Warrants to purchase an additional 5,882,353 shares of Common Stock at an exercise price of $3.00 per share (the “Series B Warrants” and collectively with the Shares and the Series A Warrants, the “Securities”). The Series B Warrants shall be exercisable immediately and expire within sixty (60) days. The Company and the Purchasers consummated the purchase and sale of the Securities (the “Closing”) and the Company raised gross proceeds of $10 million and net proceeds of approximately $9,210,000, after deducting placement agent fees, attorneys’ fees and other expenses.

The offer and sale of the Securities in the offering was registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s shelf registration statement on Form S-3, as amended (File No. 333-207976), which became effective on December 22, 2015, and Form S-3 MEF (File No. 333- 209895), filed on March 3, 2016.

Thus far, the Company has used the net proceeds of the offering for working capital purposes.

Item 3. Defaults Upon Senior Securities

Not Applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

Item 6. Exhibits

31.1		Certification of President (Principal Executive Officer and Principal Financial and Accounting Officer), Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

32.1		Certification of President, Chief Executive Officer and Principal Financial and Accounting Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101.INS		XBRL Instance Document.

101.SCH		XBRL Schema Document.

101.CAL		XBRL Calculation Linkbase Document.

101.DEF		XBRL Definition Linkbase Document.

101.LAB		XBRL Label Linkbase Document.

101.PRE		XBRL Presentation Linkbase Document.

Filed herewith

Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	NORTHWEST BIOTHERAPEUTICS, INC

Dated: May 10, 2016	By:	/s/ Linda F. Powers
		Name:	Linda F. Powers

		Title:	President and Chief Executive Officer
			Principal Executive Officer
			Principal Financial and Accounting Officer

EX-31.1 2 v439072_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Linda F. Powers, certify that:

(1) I have reviewed this quarterly report on Form 10-Q of Northwest Biotherapeutics, Inc.;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15 (f)), for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its condensed consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2016

By:	/s/ Linda F. Powers
	Name:	Linda F. Powers

	Title:	President and Chief Executive Officer
		Principal Executive Officer
		Principal Financial and Accounting Officer

EX-32.1 3 v439072_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Northwest Biotherapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2016, as filed with the Securities and Exchange Commission (the “Report”), I, Linda F. Powers, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 10, 2016

By:	/s/ Linda F. Powers
	Name:	Linda F. Powers

	Title:	President and Chief Executive Officer
		Principal Executive Officer
		Principal Financial and Accounting Officer

EX-101.INS 4 nwbo-20160331.xml XBRL INSTANCE DOCUMENT 0001072379 2015-01-01 2015-03-31 0001072379 2016-01-01 2016-03-31 0001072379 2016-02-01 2016-02-29 0001072379 2016-03-31 0001072379 2016-05-06 0001072379 2015-12-31 0001072379 2014-12-31 0001072379 2015-03-31 0001072379 us-gaap:CommonStockMember 2015-12-31 0001072379 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001072379 us-gaap:RetainedEarningsMember 2015-12-31 0001072379 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0001072379 us-gaap:CommonStockMember 2016-01-01 2016-03-31 0001072379 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-03-31 0001072379 us-gaap:RetainedEarningsMember 2016-01-01 2016-03-31 0001072379 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-03-31 0001072379 us-gaap:CommonStockMember 2016-03-31 0001072379 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0001072379 us-gaap:RetainedEarningsMember 2016-03-31 0001072379 us-gaap:AccumulatedTranslationAdjustmentMember 2016-03-31 0001072379 nwbo:MortgageLoanMember 2016-01-01 2016-03-31 0001072379 us-gaap:ConvertibleNotesPayableMember 2016-01-01 2016-03-31 0001072379 us-gaap:ConvertibleNotesPayableMember 2015-01-01 2015-03-31 0001072379 nwbo:MortgageLoanMember 2015-01-01 2015-03-31 0001072379 us-gaap:FairValueInputsLevel1Member 2016-03-31 0001072379 us-gaap:FairValueInputsLevel2Member 2016-03-31 0001072379 us-gaap:FairValueInputsLevel3Member 2016-03-31 0001072379 us-gaap:FairValueInputsLevel1Member 2015-12-31 0001072379 us-gaap:FairValueInputsLevel2Member 2015-12-31 0001072379 us-gaap:FairValueInputsLevel3Member 2015-12-31 0001072379 nwbo:WarrantLiabilityMember 2016-01-01 2016-03-31 0001072379 nwbo:QuantitativeInformationOneMember 2016-03-31 0001072379 nwbo:QuantitativeInformationOneMember 2016-01-01 2016-03-31 0001072379 us-gaap:LeaseholdImprovementsMember 2016-03-31 0001072379 us-gaap:FurnitureAndFixturesMember 2016-03-31 0001072379 us-gaap:ComputerEquipmentMember 2016-03-31 0001072379 us-gaap:LeaseholdImprovementsMember 2015-12-31 0001072379 us-gaap:FurnitureAndFixturesMember 2015-12-31 0001072379 us-gaap:ComputerEquipmentMember 2015-12-31 0001072379 us-gaap:MortgagesMember 2016-01-01 2016-03-31 0001072379 us-gaap:MortgagesMember 2015-01-01 2015-03-31 0001072379 nwbo:ConvertibleNotesPayableCurrentUnsecuredIssuedTwoMember 2016-03-31 0001072379 nwbo:CommonStockOptionsMember 2016-01-01 2016-03-31 0001072379 nwbo:CommonStockWarrantsEquityTreatmentMember 2016-01-01 2016-03-31 0001072379 nwbo:CommonStockWarrantsLiabilityTreatmentMember 2016-01-01 2016-03-31 0001072379 nwbo:CommonStockOptionsMember 2015-01-01 2015-03-31 0001072379 nwbo:CommonStockWarrantsEquityTreatmentMember 2015-01-01 2015-03-31 0001072379 nwbo:CommonStockWarrantsLiabilityTreatmentMember 2015-01-01 2015-03-31 0001072379 nwbo:ConvertibleNotesMember 2016-01-01 2016-03-31 0001072379 nwbo:ConvertibleNotesMember 2015-01-01 2015-03-31 0001072379 nwbo:MortgageLoanMember 2016-03-31 0001072379 nwbo:MortgageLoanMember 2015-12-31 0001072379 us-gaap:ConvertibleDebtMember 2016-03-31 0001072379 us-gaap:ConvertibleDebtMember 2015-12-31 0001072379 nwbo:WarrantLiabilityMember 2015-12-31 0001072379 nwbo:WarrantLiabilityMember 2016-03-31 0001072379 nwbo:SeriesWarrantsMember 2016-02-01 2016-02-29 0001072379 nwbo:SeriesWarrantsMember 2016-02-29 0001072379 nwbo:SeniorConvertibleNotesMember 2016-03-31 0001072379 nwbo:SeriesBWarrantsMember 2016-02-01 2016-02-29 0001072379 nwbo:SeriesBWarrantsMember 2016-02-29 0001072379 nwbo:SeriesCWarrantsMember 2016-02-01 2016-02-29 0001072379 nwbo:SeriesCWarrantsMember 2016-02-29 0001072379 us-gaap:PrivatePlacementMember 2016-01-01 2016-03-31 0001072379 us-gaap:PrivatePlacementMember 2016-03-31 0001072379 nwbo:SeniorConvertibleNotesMember 2016-01-01 2016-03-31 0001072379 nwbo:NotesPayableMember 2016-03-31 0001072379 us-gaap:SecondMortgageMember 2016-03-31 0001072379 us-gaap:SecondMortgageMember nwbo:MortgageLoansDueAugust2016Member 2016-03-31 0001072379 us-gaap:SecondMortgageMember nwbo:MortgageLoansDueNovember2016Member 2016-03-31 0001072379 us-gaap:ForeignCurrencyGainLossMember 2016-01-01 2016-03-31 0001072379 nwbo:CognateBioservicesMember 2016-01-01 2016-03-31 0001072379 nwbo:CognateBioservicesMember 2015-01-01 2015-03-31 0001072379 nwbo:QuantitativeInformationTwoMember 2016-03-31 0001072379 nwbo:QuantitativeInformationTwoMember 2016-01-01 2016-03-31 0001072379 nwbo:NotesPayableCurrentUnsecuredIssuedOneMember 2016-03-31 0001072379 nwbo:NotesPayableCurrentUnsecuredIssuedOneMember 2015-12-31 0001072379 nwbo:ConvertibleNotesPayableCurrentUnsecuredIssuedOneMember 2016-03-31 0001072379 nwbo:ConvertibleNotesPayableCurrentUnsecuredIssuedOneMember 2015-12-31 0001072379 nwbo:NotePayableMember 2016-03-31 0001072379 nwbo:NotePayableMember 2015-12-31 0001072379 nwbo:NoteOneMember 2016-01-01 2016-03-31 0001072379 nwbo:NoteTwoMember 2016-01-01 2016-03-31 0001072379 nwbo:PropertyAcquisitionAndConstructionMember 2016-03-31 0001072379 nwbo:PropertyAcquisitionAndConstructionMember 2015-12-31 0001072379 nwbo:CognateBioservicesMember 2016-03-31 0001072379 nwbo:CognateBioservicesMember 2015-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 10-Q false 2016-03-31 2016 Q1 NORTHWEST BIOTHERAPEUTICS INC 0001072379 --12-31 Accelerated Filer NWBO 101740440

11688000

21813000

746000

886000

1065000

1402000

13499000

24101000

48360000

46157000

214000

349000

153000

190000

48727000

46696000

62226000

70797000

8726000

11721000

6366000

5455000

185000

934000

1189000

1309000

6200000

14457000

27982000

57806000

64930000

10613000

10543000

10613000

10543000

68419000

75473000

102000

96000

634696000

630613000

641368000 635262000

377000

-123000

-6193000

-4676000

62226000

70797000

10950000

11144000

194000

236000

194000

236000

19625000

13440000

3400000

4275000

23025000

17715000

-22831000

-17479000

-23158000

13525000

793000

718000

-46433000

-6106000

349000

-1434000

97688000

69406000

-0.06

-0.67

68000

-500000

-46501000

-5606000

96000

630613000

-635262000

-123000

95858

-6106000

102000

634696000

-641368000

377000

101740

500000

-337000

-378000

-3116000

103000

912000

-17582000

-17595000

1133000

2683000

-1133000

-2408000

0 6359000 3644000 279000

4997000

138000

13390000

3170000

3000

13000

234000

209000

-349000 -37000 0

3651000

9244000

8510000

634000

-15000

-10125000

-10220000

-275000

334000

275000

428000

307000

0 299000

6200000

4500000

32000000

6200000

14457000

27982000

-13525000

3.49

0.869

0.013

P3Y1M6D

69000

25000

602000

69000

25000

597000

229000

216000

13000

3000

137000

216000

207000

321000

70000

105000

400000

300000

100000

1119000

0.06

46009000

32678000

1551000

26876000

15839000

1551000

15830000

12500000

1743000

2797000

27267441000

16791000

42715146000

4.4 11.86 3.53

12000 11000 50000 50000

321000

468000

387000

457000

0.001

40000000

0.001

450000000

101740440

95858087

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Basis of Presentation</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 44pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The accompanying unaudited condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of March 31, 2016, condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015, condensed consolidated statements of comprehensive loss for the three months ended March 31, 2016 and 2015, condensed consolidated statement of stockholders’ equity (deficit) for the three months ended March 31, 2016, and the condensed consolidated statements of cash flows for the three months ended March 31, 2016 and 2015 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months ended March 31, 2016 are not necessarily indicative of results to be expected for the year ending December 31, 2016 or for any future interim period. The condensed consolidated balance sheet at March 31, 2016 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2015, and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on March 16, 2016.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Warrant Liability</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company accounts for certain common stock warrants outstanding as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company's statements of operations. The fair value of the warrants issued by the Company in connection the Conversion Transaction has been estimated using a Monte Carlo simulation.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Foreign Currency Translation and Transactions</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i> </i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has operations in Germany, the United Kingdom and Canada, in addition to the U.S. Assets and liabilities are translated into U.S. dollars using end of period exchange rates and revenues and expenses are translated into U.S. dollars using weighted average rates. Foreign currency translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) within stockholders’ equity (deficit).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the three months ended March 31, 2016, the Company recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.5</font> million of foreign currency translation gain primarily due to the strengthening of the U.S. dollar relative to the euro and British pound sterling.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Foreign currency transaction losses are recognized in the Consolidated Statements of Operations as incurred.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>4. Fair Value Measurements</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of March 31, 2016 and December 31, 2015 (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%" colspan="11"> <div style="CLEAR:both;CLEAR: both"> Fair value measured at March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> Quoted prices in active</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Significant other</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Significant</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Fair value at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">markets</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">observable inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">unobservable inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(Level 1)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(Level 2)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(Level 3)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both">Derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both">14,457</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both">14,457</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%" colspan="11"> <div style="CLEAR:both;CLEAR: both"> Fair value measured at December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> Quoted prices in active</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Significant other</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Significant</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Fair value at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">markets</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">observable inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">unobservable inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(Level 1)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(Level 2)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(Level 3)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both">Derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both">27,982</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both">27,982</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">There were no transfers between Level 1, 2 or 3 during the three-month period ended March 31, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table presents changes in Level 3 liabilities measured at fair value for the three-month period ended March 31, 2016. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (in thousands).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Warrant</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Liability</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Balance - January 1, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">27,982</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Change in fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(13,525)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Balance  March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">14,457</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company’s warrant liabilities are measured at fair value using the Monte Carlo simulation valuation methodology. A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy for the three months ended March 31, 2016 is as follows:</div>    <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="54%"> <div style="CLEAR:both;CLEAR: both"> Date of valuation</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">January 1, 2016</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="2%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div style="CLEAR:both;CLEAR: both">Strike price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.49</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.38</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div style="CLEAR:both;CLEAR: both">Volatility (annual)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">86.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">85.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div style="CLEAR:both;CLEAR: both">Risk-free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div style="CLEAR:both;CLEAR: both">Contractual term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div style="CLEAR:both;CLEAR: both">Dividend yield (per share)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="COLOR: #1f497d"><i> </i></font>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of March 31, 2016 and December 31, 2015 (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%" colspan="11"> <div style="CLEAR:both;CLEAR: both"> Fair value measured at March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> Quoted prices in active</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Significant other</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Significant</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Fair value at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">markets</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">observable inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">unobservable inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(Level 1)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(Level 2)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(Level 3)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both">Derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both">14,457</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both">14,457</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%" colspan="11"> <div style="CLEAR:both;CLEAR: both"> Fair value measured at December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> Quoted prices in active</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Significant other</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Significant</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Fair value at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">markets</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">observable inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">unobservable inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(Level 1)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(Level 2)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(Level 3)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div style="CLEAR:both;CLEAR: both">Derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both">27,982</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div style="CLEAR:both;CLEAR: both">27,982</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company’s warrant liabilities are measured at fair value using the Monte Carlo simulation valuation methodology. A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy for the three months ended March 31, 2016 is as follows:</div>    <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="54%"> <div style="CLEAR:both;CLEAR: both"> Date of valuation</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">January 1, 2016</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="2%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div style="CLEAR:both;CLEAR: both">Strike price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.49</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.38</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div style="CLEAR:both;CLEAR: both">Volatility (annual)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">86.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">85.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div style="CLEAR:both;CLEAR: both">Risk-free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div style="CLEAR:both;CLEAR: both">Contractual term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div style="CLEAR:both;CLEAR: both">Dividend yield (per share)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>6. Notes Payable</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>2014 Convertible Senior Notes</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has Convertible Senior Notes of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.6</font> million, net of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.4</font> million deferred offering cost as of March 31, 2016 with an interest rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font>% and conversion price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.60</font>. The Company has remaining $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million in escrowed interest payments, which is sufficient to fund, when due, the total aggregate amount of the six scheduled semi-annual interest payments during the remaining term of the notes, excluding additional interest, if any.</div> </div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table shows the details of interest expenses related to 2014 Convertible Senior Notes for the three months ended March 31, 2016 and 2015, respectively (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%" colspan="5"> <div>For the three months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%" colspan="5"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Contractual interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>137</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>216</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Amortization of debt issuance costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>70</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>105</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Total interest expense on the convertible senior notes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>207</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>321</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Mortgage Loan</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong> </strong>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has two <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12</font>% mortgage loans that are secured by the UK facility with principal of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11.3</font> million, net of deferred financing costs of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.3</font> million. $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.7</font> million of the mortgage loans are due in August 2016 and the remainder in November 2016.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Interest expense was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.4</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.3</font> million for the three months ended March 31, 2016 and 2015, respectively, which includes $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1</font> million amortization of deferred offering financing costs in both periods.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Other Notes Payable</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Notes payable consist of the following at March 31, 2016 and December 31, 2015 (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="65%"> <div>Notes payable  current</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>12% unsecured originally due July 2011 - in dispute (1)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>934</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>934</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>934</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>934</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="65%"> <div>Convertible notes payable, net - current</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>6% unsecured (2)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="65%"> <div>Note payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>6% due on demand (3)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Total notes payable, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,119</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,119</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">(1) This $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.934</font> million note, which was originally due in July 2011 is currently under dispute with the creditor as to the validity of the note payable balance, which the Company believes has already been paid in full and is not outstanding.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">(2) This $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.135</font> million note as of March 31, 2016 consists of two separate <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6</font>% notes in the amounts of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.110</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.025</font> million. In regard to the $0.110 million note, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the $0.025 million note, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">(3) This $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.050</font> million demand note as of March 31, 2016 is held by an officer of the Company. The holder has made no demand for payment, but reserves the right to make a demand at any time.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following table shows the details of interest expenses related to 2014 Convertible Senior Notes for the three months ended March 31, 2016 and 2015, respectively (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%" colspan="5"> <div>For the three months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%" colspan="5"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Contractual interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>137</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>216</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Amortization of debt issuance costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>70</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>105</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Total interest expense on the convertible senior notes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>207</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>321</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Notes payable consist of the following at March 31, 2016 and December 31, 2015 (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="65%"> <div>Notes payable  current</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>12% unsecured originally due July 2011 - in dispute (1)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>934</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>934</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>934</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>934</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="65%"> <div>Convertible notes payable, net - current</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>6% unsecured (2)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="65%"> <div>Note payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>6% due on demand (3)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Total notes payable, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,119</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,119</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">(1) This $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.934</font> million note, which was originally due in July 2011 is currently under dispute with the creditor as to the validity of the note payable balance, which the Company believes has already been paid in full and is not outstanding.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">(2) This $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.135</font> million note as of March 31, 2016 consists of two separate <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6</font>% notes in the amounts of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.110</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.025</font> million. In regard to the $0.110 million note, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the $0.025 million note, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">(3) This $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.050</font> million demand note as of March 31, 2016 is held by an officer of the Company. The holder has made no demand for payment, but reserves the right to make a demand at any time.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented (in thousands): </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%" colspan="5"> <div>For the three months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%" colspan="5"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Common stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,551</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,551</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Common stock warrants - equity treatment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>26,876</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>15,830</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Common stock warrants - liability treatment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>15,839</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>12,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Convertible notes and accrued interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,743</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,797</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Potentially dilutive securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>46,009</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>32,678</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

10000000 0

756000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>10. Contingencies</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b> </b>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Derivative and Class Action Litigation</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In 2014, as previously reported, the Company received demand letters from three purported individual shareholders seeking to inspect our corporate books and records pursuant to Section 220 of the Delaware General Corporation Law. The demand letters were all substantially similar, and claimed that their purpose is to investigate possible mismanagement and breaches of fiduciary duty by the Company’s directors and officers.  They requested a range of documents.  On November 13, 2014, one of the purported shareholders filed a complaint in the Delaware Court of Chancery seeking to enforce her books and records demand. The Company reached negotiated agreements and provided limited records, under confidentiality agreements. On July 16, 2015, the parties filed, and the court entered, a stipulation dismissing the case.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="justify">On June 19, 2015, two of the purported shareholders filed a complaint purportedly suing on behalf of a class of similarly situated shareholders and derivatively on behalf of the Company in the Delaware Court of Chancery.  The lawsuit names Cognate BioServices, Inc., Toucan Partners, Toucan Capital Fund III, our CEO Linda Powers and the Company’s Board of Directors as defendants, and names the Company as a “nominal defendant” with respect to the derivative claims.  The complaint generally objects to certain transactions between the Company and Cognate and the Toucan entities, in which Cognate and the Toucan entities provided services and financing to the Company, or agreed to conversion of debts owed to them by the Company into equity.  The complaint seeks unspecified monetary relief for the Company and the plaintiffs, and various forms of equitable relief, including disgorgement of allegedly improper benefits, rescission of the challenged transactions, and an order forbidding similar transactions in the future.  On September 1, 2015, the Company and other named defendants filed motions to dismiss.  In response, the plaintiffs filed an amended complaint on November 6, 2015. The Company and the other named defendants filed motions to dismiss plaintiffs’ amended complaint on January 19, 2016. The plaintiffs filed an answering brief in opposition to the motion to dismiss on April 4, 2016. The Company intends to continue to vigorously defend the case.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On November 19, 2015, a third purported shareholder who had sought corporate books and records filed a complaint in the U.S. District Court for the District of Maryland, claiming to sue derivatively on behalf of the Company. The complaint names the Company’s Board of Directors, Toucan Capital Fund III, L.P., Toucan General II, LLC, Toucan Partners, LLC, and Cognate as defendants, and names the Company as a nominal defendant. The complaint claims that the plaintiff made a demand on the Company’s Board of Directors to commence an action against the Company’s directors and its CEO and that the plaintiff commenced the derivative action after not receiving a response to the demand letter within an allegedly “sufficient time.” The complaint further claims that the Company purportedly overcompensated Cognate and Toucan for certain services and loans in payments of stock, and that the Company’s CEO, Ms. Powers, benefited from these transactions with Cognate and Toucan, which she allegedly owns or controls. The complaint asserts that the alleged overpayments unjustly enriched Ms. Powers, Toucan, and Cognate. The Complaint also claims that the Company’s directors breached their fiduciary duties of loyalty and good faith to the Company by authorizing the payments to Cognate. Finally, the complaint claims that Ms. Powers, Cognate, and Toucan aided and abetted the directors’ breaches of fiduciary duties by causing the board to enter into the agreements with Cognate. The plaintiff seeks an award of unspecified damages to the Company and seeks equitable remedies, including disgorgement by Ms. Powers, Toucan, and Cognate of the allegedly improper benefits received as a result of the disputed transactions. The plaintiff also seeks costs and disbursements associated with bringing suit, including attorneys’ fees and expert fees. On February 2, 2016, plaintiff and defendants filed a joint motion to stay the proceedings pending an investigation by a special committee of the Company’s Board of Directors into the allegations asserted in the demand letter and underlying the lawsuit. </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Class Action Securities Litigation</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On August 26, 2015, a purported shareholder of the Company filed a putative class action complaint in the U.S. District Court for the District of Maryland.  The lawsuit names the Company and Ms. Powers as defendants.  On December 14, 2015, the court appointed two lead plaintiffs. The Lead Plaintiffs filed an amended complaint on February 12, 2016, purportedly on behalf of all of those who purchased common stock in NW Bio between January 13, 2014 and August 21, 2015. The amended complaint generally claims that the defendants violated Section 10(b) and Section 20(a) of the Securities Exchange Act of 1934 by making misleading statements and/or omissions on a variety of subjects, including the status and results of the Company’s DCVax trials.  The amended complaint seeks unspecified damages, attorneys’ fees, and costs. The Company and Ms. Powers filed a motion to dismiss plaintiffs’ amended complaint on April 12, 2016.  The Company intends to vigorously defend the case.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Shareholder Books and Record Demand</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On December 7, 2015, the Company received a letter on behalf of shareholders demanding to inspect certain corporate books and records pursuant to Section 220 of the Delaware General Corporation Law. The demand letter claimed that its purpose was to investigate: (1) allegedly improper transactions, misconduct, and mismanagement by directors and an officer of the Company; (2) the possible breach of fiduciary duty by certain directors and officers of the Company; and (3) the independence and disinterestedness of the Company’s board, to determine whether a pre-suit demand would be necessary before commencing any derivative action on behalf of the Company. The Company has appointed a special committee of its Board of Directors consisting of independent and disinterested directors to investigate the allegations set forth in the demand letter, as well as the allegations asserted in the litigation summarized above. The Company also is in ongoing discussions with the shareholders demanding corporate books and records.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <font style="FONT-FAMILY:Times New Roman, Times, Serif"> </font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

11700000

44300000

14500000

6400000

27982000

14457000

48589000

46373000

135000

50000

756000

5155000

8799000

5882353

1.70

2941177

2.25

44300000 6200000

0.05

6.60

1000000

8800000

12058825000 3.04 10000000

9200000

5882353

3.00

2941177

4.00

0.07 0.05

2.125

1.25

294118

P5Y

10600000

400000

50000

0.12

11300000

300000

4700000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>11. Subsequent Events<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-stretch: normal; font-size-adjust: none"> As the Company previously reported on Form 8-K, on April 26, 2016, the Company received a letter (the “Letter”) from the staff of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Staff had reviewed certain stock issuances by the Company to Cognate BioServices, Inc. (“Cognate”), and had determined that those issuances did not comply with Nasdaq Rules 5635(c) and (d). The Letter has no immediate effect on the listing of the Company’s common stock. The Letter allows the Company until June 10, 2016 to submit a remediation plan to regain compliance with Nasdaq’s rules 5635(c) and (d). If the plan is accepted, Nasdaq can allow up to 6 months from the date of the Letter for the Company to evidence compliance with these rules.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-stretch: normal; font-size-adjust: none">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-stretch: normal; font-size-adjust: none"> The Company intends to take the appropriate steps to address the issues raised by the Nasdaq Staff as quickly as possible and is already in discussions with the Nasdaq Staff about two approaches to remediation. The Company intends to submit a remediation plan to Nasdaq promptly for its approval.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

10000000

6000

9994000

5882

500000

11200000

14700000

2.38

0.859

0.009

P3Y

5200000

6400000

934000

135000

50000

110000

25000

47893000

45681000

6400000

5500000

On March 3, 2016, the Company entered into a financing under which it sold 5.9 million common shares and 12.1 million Series A, B and C warrants to unrelated investors on terms more favorable than the existing terms of Cognates shares. The sale of common shares had an effective price of $1.7, which triggered a most favored nation obligation which would result in an obligation to issue 6.0 million shares to Cognate. However, these shares have not been issued, and the Company is in active negotiations with Cognate seeking to modify these arrangements.

0 50000 0 520000

257000

428000

1.70 3405671000

This $0.934 million note, which was originally due in July 2011 is currently under dispute with the creditor as to the validity of the note payable balance, which the Company believes has already been paid in full and is not outstanding. This $0.135 million note as of March 31, 2016 consists of two separate 6% notes in the amounts of $0.110 million and $0.025 million. In regard to the $0.110 million note, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the $0.025 million note, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents. This $0.050 million demand note as of March 31, 2016 is held by an officer of the Company. The holder has made no demand for payment, but reserves the right to make a demand at any time.

EX-101.SCH 5 nwbo-20160331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:definitionLink link:calculationLink 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Organization and Description of Business and Recent Developments link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Liquidity and Financial Condition link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Property, Plant and Equipment link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Notes Payable link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Net Loss per Share Applicable to Common Stockholders link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Stockholders' Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Contingencies link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Notes Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Net Loss per Share Applicable to Common Stockholders (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Stockholders' Equity (Deficit) (Tables) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Liquidity and Financial Condition (Details Textual) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Fair Value Measurements (Details 1) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Fair Value Measurements (Details 2) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Property, Plant and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Property, Plant and Equipment (Details Textual) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Notes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Notes Payable (Details 1) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Notes Payable (Details Textual) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Net Loss per Share Applicable to Common Stockholders (Details) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - Related Party Transactions (Details Textual) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - Stockholders' Equity (Deficit) (Details) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - Stockholders' Equity (Deficit) (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 nwbo-20160331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 nwbo-20160331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 nwbo-20160331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Disclosures [Text Block] Property, Plant and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Debt Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Related Party Transactions Disclosure [Text Block] Stockholders' Equity Note [Abstract] Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events [Text Block] Statement Of Financial Position [Abstract] Statement [Table] Statement, Scenario [Axis] Scenario, Unspecified [Domain] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year Restricted Cash and Investments, Current Restricted cash - interest payments held in escrow Assets, Noncurrent [Abstract] Non-current assets: Property, Plant and Equipment, Net, Total Property, plant and equipment, net Property, Plant and Equipment, Net Restricted Cash and Investments, Noncurrent Restricted cash - interest payments held in escrow, net of current portion Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Other Assets, Noncurrent Other assets Assets, Total Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accounts Payable, Related Parties, Current Accounts payable to related party Accounts payable, related party (in dollars) Accrued Liabilities, Current Accrued expenses (includes related party of $12 and $11 as of March 31, 2016 and December 31, 2015, respectively) Convertible Notes, Net (Includes Related Party Of 0 and 3,588 In 2012 and 2011, Respectively) Convertible notes, net (includes related party note of $50 as of March 31, 2016 and December 31, 2015) Notes Payable, Current, Total Note payable - in dispute Notes payable - current Secured Long-term Debt, Noncurrent Mortgage loan (net of deferred financing cost of $321 and $468 as of March 31, 2016 and December 31, 2015, respectively) Liabilities, Noncurrent [Abstract] Non-current liabilities: Convertible Notes Payable, Noncurrent Convertible note (net of deferred financing cost of $387 and $457 as of March 31, 2016 and December 31, 2015, respectively) Convertible notes payable, net - non current Accrued Environmental Loss Contingencies, Current Environmental remediation liability Commitments and Contingencies Commitments and Contingencies Preferred Stock, Value, Issued Preferred stock ($0.001 par value); 40,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively Common Stock, Value, Issued Common stock ($0.001 par value); 450,000,000 shares authorized; 101,740,440 and 95,858,087 shares issued and outstanding as of March 31, 2016 and December 31, 2014, respectively Additional Paid In Capital, Common Stock Additional paid-in capital Development Stage Enterprise Deficit Accumulated During Development Stage1 Accumulated deficit Cumulative net losses reported during the development stage. Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive gain (loss) Stockholders' Equity Attributable To Parent Total stockholders' equity (deficit) Balance Balance Liabilities and Equity Total liabilities and stockholders' equity (deficit) Accounting Policies [Abstract] Basis of Accounting, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Warrant Liability Policy [Policy Text Block] Disclosure of accounting policy for warrant liability. Environmental Cost, Expense Policy [Policy Text Block] Foreign Currency Transactions and Translations Policy [Policy Text Block] Comprehensive Loss Policy [Policy Text Block] Disclosure of accounting policy for comprehensive loss. Research and Development Expense, Policy [Policy Text Block] Significant Accounting Policies [Policy Text Block] Disclosure of accounting policy for Significant Accounting Policies. New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] Property, Plant and Equipment [Table Text Block] Interest Income and Interest Expense Disclosure [Table Text Block] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule Of Warrant Activity [Table Text Block] Organization, Consolidation and Presentation Of Financial Statements [Abstract] Class Of Stock [Domain] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Equity Components [Axis] Equity Component [Domain] Sale of Stock [Axis] Sale of Stock [Domain] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Title of Individual [Axis] Title Of Individual With Relationship To Entity [Domain] Mortgage Loans on Real Estate, Loan Type [Axis] Mortgage Loans on Real Estate, Loan Type [Domain] Related Party [Axis] Summary of Significant Accounting Policies [Table] Related Party [Domain] Schedule of Fair Value of Separate Accounts by Major Category of Investment [Axis] Research and Development Expense Research and development Accrued Environmental Loss Contingencies, Noncurrent Environmental remediation liabilities Site Contingency, Loss Exposure in Excess of Accrual, High Estimate Site Contingency, Loss Exposure in Excess of Accrual, Low Estimate Site Contingency, Loss Exposure in Excess of Accrual, Best Estimate Condensed Consolidated Balance Sheets [Parenthetical] [Abstract] Condensed Consolidated Balance Sheets Parenthetical. Short-term Debt, Type [Axis] Accrued Expenses Related Party Accrued expenses, related party net (in dollars) The aggregate obligations owed to related parties at the financial statement date. Used to reflect the current portion of the liabilities (due within one year at or within the normal operating cycle if longer). Convertible Notes Payable Related Parties Current Convertible notes payable current related parties, net (in dollars) The amount for convertible notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Preferred Stock, Par Or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Derivative Liability, Current Derivative liability Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Derivative Instrument [Axis] Derivative Contract [Domain] Warrant Liability [Member] Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Balance Balance Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss) Change in fair value Quantitative Information [Axis] Quantitative Information [Domain] Quantitative Information One [Member] Quantitative Information Two [Member] Range [Axis] Range [Domain] Share Price Strike price Strike price Fair Value Assumptions, Expected Volatility Rate Volatility (annual) Volatility (annual) Fair Value Assumptions, Risk Free Interest Rate Risk-free rate Risk-free rate Fair Value Assumptions, Expected Term Contractual term (years) Fair Value Assumptions, Expected Dividend Rate Dividend yield (per share) Leasehold Improvements [Member] Leasehold improvements [Member] Furniture and Fixtures [Member] Office furniture and equipment [Member] Computer Equipment [Member] Computer equipment and software [Member] Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation Geographical [Axis] Geographical [Domain] Depreciation Income Statement [Abstract] Revenues [Abstract] Revenues: Revenue from Grants Research grant and other Revenue, Net Total revenues Costs and Expenses [Abstract] Operating costs and expenses: General and Administrative Expense General and administrative Operating Costs and Expenses Total operating costs and expenses Operating expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expense): Net Income (Loss) Attributable To Parent Net loss Net loss Net Loss Net loss Net earnings (loss) - basic Net (loss)/income Schedule of Long-term Debt Instruments [Table] Short-Term Debt, Type [Domain] Notes Payable Current, Unsecured, Issued One [Member] Convertible Notes Payable Current, Unsecured, Issued One [Member] Financial Instrument [Axis] Convertible Debt, Current Convertible notes payable, net - current Notes Payable, Noncurrent Notes payable Convertible Notes Payable Current Unsecured Issued Two [Member] Convertible Notes Payable Related Parties Current Unsecured Issued Three [Member] Notes Payable [Member] Third Party [Axis] Third Party [Domain] Third Party [Domain] Income Statement Location [Axis] Income Statement Location [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Senior Convertible Notes [Member] 2014 Convertible Notes Member Debt Conversion, Name [Domain] Debt Conversion Description [Axis] Debt Conversion, Converted Instrument, Amount Debt Conversion, Converted Instrument, Amount Debt Instrument, Convertible, Conversion Price Debt Instrument, Interest Rate, Stated Percentage Schedule of Related Party Transactions, by Related Party [Table] Cognate Bioservices [Member] Award Type [Axis] Award Type [Domain] Condition [Axis] Condition [Domain] Products and Services [Axis] Products and Services [Domain] Extinguishment of Debt [Axis] Extinguishment of Debt, Type [Domain] Shareholders Deficit [Table] Shareholders Deficit [Line Items] EX-101.PRE 9 nwbo-20160331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2016	May. 06, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1
Entity Registrant Name	NORTHWEST BIOTHERAPEUTICS INC
Entity Central Index Key	0001072379
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	NWBO
Entity Common Stock, Shares Outstanding		101,740,440

XML 11 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 11,688	$ 21,813
Restricted cash - interest payments held in escrow	746	886
Prepaid expenses and other current assets	1,065	1,402
Total current assets	13,499	24,101
Non-current assets:
Property, plant and equipment, net	48,360	46,157
Restricted cash - interest payments held in escrow, net of current portion	214	349
Other assets	153	190
Total non-current assets	48,727	46,696
Total assets	62,226	70,797
Current liabilities:
Accounts payable	8,726	11,721
Accounts payable to related party	6,366	5,455
Accrued expenses (includes related party of $12 and $11 as of March 31, 2016 and December 31, 2015, respectively)	1,189	1,309
Convertible notes, net (includes related party note of $50 as of March 31, 2016 and December 31, 2015)	185	185
Note payable - in dispute	934	934
Mortgage loan (net of deferred financing cost of $321 and $468 as of March 31, 2016 and December 31, 2015, respectively)	10,950	11,144
Environmental remediation liability	6,200	6,200
Shares payable to related party	8,799	0
Derivative liability	14,457	27,982
Total current liabilities	57,806	64,930
Non-current liabilities:
Convertible note (net of deferred financing cost of $387 and $457 as of March 31, 2016 and December 31, 2015, respectively)	10,613	10,543
Total non-current liabilities	10,613	10,543
Total liabilities	$ 68,419	$ 75,473
Commitments and Contingencies
Stockholders' equity (deficit):
Preferred stock ($0.001 par value); 40,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively	$ 0	$ 0
Common stock ($0.001 par value); 450,000,000 shares authorized; 101,740,440 and 95,858,087 shares issued and outstanding as of March 31, 2016 and December 31, 2014, respectively	102	96
Additional paid-in capital	634,696	630,613
Accumulated deficit	(641,368)	(635,262)
Accumulated other comprehensive gain (loss)	377	(123)
Total stockholders' equity (deficit)	(6,193)	(4,676)
Total liabilities and stockholders' equity (deficit)	$ 62,226	$ 70,797

XML 12 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Accrued expenses, related party net (in dollars)	$ 12	$ 11
Convertible notes payable current related parties, net (in dollars)	$ 50	$ 50
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	40,000,000	40,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	450,000,000	450,000,000
Common stock, shares issued	101,740,440	95,858,087
Common stock, shares outstanding	101,740,440	95,858,087
Convertible Debt [Member]
Deferred Finance Costs, Noncurrent, Net (in dollars)	$ 387	$ 457
Mortgage Loan [Member]
Deferred Finance Costs, Noncurrent, Net (in dollars)	$ 321	$ 468

XML 13 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Research grant and other	$ 236	$ 194
Total revenues	236	194
Operating costs and expenses:
Research and development	13,440	19,625
General and administrative	4,275	3,400
Total operating costs and expenses	17,715	23,025
Loss from operations	(17,479)	(22,831)
Other income (expense):
Change in fair value of derivative liability	13,525	(23,158)
Interest expense	(718)	(793)
Foreign currency transaction (loss) gain	(1,434)	349
Net loss	$ (6,106)	$ (46,433)
Net loss per share applicable to common stockholders - basic and diluted (in dollars per share)	$ (0.06)	$ (0.67)
Weighted average shares used in computing basic and diluted loss per share (in shares)	97,688	69,406

XML 14 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net loss	$ (6,106)	$ (46,433)
Other comprehensive income (loss)
Foreign currency translation adjustment	500	(68)
Total comprehensive loss	$ (5,606)	$ (46,501)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 15 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - 3 months ended Mar. 31, 2016 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Cumulative Translation Adjustment [Member]
Balance at Dec. 31, 2015	$ (4,676)	$ 96	$ 630,613	$ (635,262)	$ (123)
Balance (in shares) at Dec. 31, 2015		95,858
Issuance of common stock and warrants for cash in a registered direct offering	10,000	$ 6	9,994	0	0
Issuance of common stock and warrants for cash in a registered direct offering (in shares)		5,882
Offering cost related to registered direct offering	(756)	$ 0	(756)	0	0
Shares payment due to Cognate BioServices	(5,155)	0	(5,155)	0	0
Net loss	(6,106)	0	0	(6,106)	0
Cumulative translation adjustment	500	0	0	0	500
Balance at Mar. 31, 2016	$ (6,193)	$ 102	$ 634,696	$ (641,368)	$ 377
Balance (in shares) at Mar. 31, 2016		101,740

XML 16 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash Flows from Operating Activities:
Net Loss	$ (6,106)	$ (46,433)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization	13	3
Amortization of deferred financing cost	209	234
Change in fair value of derivatives	(13,525)	23,158
Accrued interest converted to common stock	0	(349)
Stock issued to Cognate BioServices under Cognate Agreements	3,644	6,359
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	337	(279)
Accounts payable and accrued expenses	(3,116)	(378)
Related party accounts payable and accrued expenses	912	103
Other non-current assets	37	0
Net cash used in operating activities	(17,595)	(17,582)
Cash Flows from Investing Activities:
Purchase of property, plant and equipment	(2,683)	(1,133)
Funding of escrow - convertible notes	275	0
Net cash used in investing activities	(2,408)	(1,133)
Cash Flows from Financing Activities:
Proceeds from mortgage loan	0	4,997
Deferred offering cost related to mortgage loan	0	(138)
Proceeds from issuance of common stock and warrants in a registered direct offering	10,000	0
Offering cost related to registered direct offering	(756)	0
Proceeds from exercise of warrants	0	3,651
Net cash provided by financing activities	9,244	8,510
Effect of exchange rate changes on cash and cash equivalents	634	(15)
Net decrease in cash and cash equivalents	(10,125)	(10,220)
Cash and cash equivalents at beginning of year	21,813	13,390
Cash and cash equivalents at end of year	11,688	3,170
Supplemental schedule of non-cash investing and financing activities:
Accrued Exit Fee incurred from mortgage loan	0	50
Cashless warrant exercise on warrant liability	0	520
Increase in accounts payable related to UK property	0	257
Interest payment on convertible note from escrow	0	428
Redeemable security settlement	0	299
Mortgage Loan [Member]
Supplemental disclosure of cash flow information
Interest Payments	(334)	(307)
Convertible Notes Payable [Member]
Supplemental disclosure of cash flow information
Interest Payments	$ (275)	$ (428)

XML 17 R8.htm IDEA: XBRL DOCUMENT

Organization and Description of Business and Recent Developments

3 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1. Organization and Description of Business and Recent Developments

XML 18 R9.htm IDEA: XBRL DOCUMENT

Liquidity and Financial Condition

3 Months Ended

Mar. 31, 2016

Liquidity [Abstract]

Liquidity and Financial Condition [Text Block]

2. Liquidity and Financial Condition

For the three months ended March 31, 2016 and 2015, we recognized a net loss of $6.1 million and a net loss of $46.4 million, respectively.

XML 19 R10.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

3. Summary of Significant Accounting Policies

Basis of Presentation

Use of Estimates

Warrant Liability

Environmental Remediation Liabilities

Foreign Currency Translation and Transactions

Foreign currency transaction losses are recognized in the Consolidated Statements of Operations as incurred.

Comprehensive Loss

Research and Development Costs

For the three months ended March 31, 2016 and 2015, the Company recognized research and development costs of $13.4 million and $19.6 million, respectively.

Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2015 Annual Report.

Recent Accounting Pronouncements

XML 20 R11.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

4. Fair Value Measurements

The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of March 31, 2016 and December 31, 2015 (in thousands):

Fair value measured at March 31, 2016

Quoted prices in active

Significant other

Significant

Fair value at

markets

observable inputs

unobservable inputs

March 31, 2016

(Level 1)

(Level 2)

(Level 3)

Derivative liability

14,457

Fair value measured at December 31, 2015

Quoted prices in active

Significant other

Significant

Fair value at

markets

observable inputs

unobservable inputs

December 31, 2015

(Level 1)

(Level 2)

(Level 3)

Derivative liability

27,982

There were no transfers between Level 1, 2 or 3 during the three-month period ended March 31, 2016.

	Warrant
	Liability
Balance - January 1, 2016	$	27,982
Change in fair value		(13,525)
Balance – March 31, 2016	$	14,457

Date of valuation	January 1, 2016			March 31, 2016
Strike price	$	3.49		$	2.38
Volatility (annual)		86.9	%		85.9	%
Risk-free rate		1.3	%		0.9	%
Contractual term (years)		3.1			3.0
Dividend yield (per share)		0	%		0	%

The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R12.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment

3 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

5. Property, Plant and Equipment

Property and equipment consist of the following at March 31, 2016 and December 31, 2015 (in thousands):

	March 31,		December 31,
	2016		2015
Leasehold improvements	$	69	$	69
Office furniture and equipment		25		25
Computer equipment and software		602		597
UK property acquisition, construction and estimated environmental liability		47,893		45,681

		48,589		46,373
Less: accumulated depreciation		(229)		(216)
	$	48,360	$	46,157

Depreciation expense was approximately $13,000 and $3,000 for the three months ended March 31, 2016 and 2015.

XML 22 R13.htm IDEA: XBRL DOCUMENT

Notes Payable

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

6. Notes Payable

2014 Convertible Senior Notes

The following table shows the details of interest expenses related to 2014 Convertible Senior Notes for the three months ended March 31, 2016 and 2015, respectively (in thousands):

	For the three months ended
	March 31,
	2016		2015
Contractual interest	$	137	$	216
Amortization of debt issuance costs		70		105
Total interest expense on the convertible senior notes	$	207	$	321

Mortgage Loan

Other Notes Payable

Notes payable consist of the following at March 31, 2016 and December 31, 2015 (in thousands):

	March 31,		December 31,
	2016		2015
Notes payable – current
12% unsecured originally due July 2011 - in dispute (1)	$	934	$	934
		934		934
Convertible notes payable, net - current
6% unsecured (2)		135		135
		135		135
Note payable
6% due on demand (3)		50		50
		50		50

Total notes payable, net	$	1,119	$	1,119

(3) This $0.050 million demand note as of March 31, 2016 is held by an officer of the Company. The holder has made no demand for payment, but reserves the right to make a demand at any time.

XML 23 R14.htm IDEA: XBRL DOCUMENT

Net Loss per Share Applicable to Common Stockholders

3 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

7. Net Loss per Share Applicable to Common Stockholders

Options, warrants, and convertible debt outstanding were all considered anti-dilutive for the three months ended March 31, 2016, and 2015, due to net losses.

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented (in thousands):

	For the three months ended
	March 31,
	2016		2015
Common stock options		1,551		1,551
Common stock warrants - equity treatment		26,876		15,830
Common stock warrants - liability treatment		15,839		12,500
Convertible notes and accrued interest		1,743		2,797
Potentially dilutive securities		46,009		32,678

XML 24 R15.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Mar. 31, 2016

8. Related Party Transactions

Cognate BioServices, Inc.

Cognate Expenses and Accounts Payable

At March 31, 2016 and December 31, 2015, the Company owed Cognate $6.4 million and $5.5 million, respectively, for unpaid invoices for manufacturing and related services.

Share Based Payments

Shares payable to related party – most favored nation provision

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

XML 25 R16.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Deficit)

3 Months Ended

Mar. 31, 2016

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

9. Stockholders’ Equity (Deficit)

Common Stock Issuances

First Quarter 2016

Stock Purchase Warrants

The following is a summary of warrant activity for the three months ended March 31, 2016 (in thousands, except per share data):

	Number of		Weighted Average
	Warrants		Exercise Price
Outstanding as of December 31, 2015		27,267,441	$	4.40
Warrants granted in a registered direct offering		12,058,825		3.04
Additional warrants owed to Cognate as part of reset		3,405,671		1.70
Warrants expired and cancelled		(16,791)		11.86
Outstanding as of March 31, 2016		42,715,146	$	3.53

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 26 R17.htm IDEA: XBRL DOCUMENT

Contingencies

3 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

10. Contingencies

Derivative and Class Action Litigation

Class Action Securities Litigation

Shareholder Books and Record Demand

XML 27 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2016

Subsequent Events [Abstract]

Subsequent Events [Text Block]

11. Subsequent Events

XML 28 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Warrant Liability Policy [Policy Text Block]

Warrant Liability

Environmental Cost, Expense Policy [Policy Text Block]

Environmental Remediation Liabilities

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency Translation and Transactions

Foreign currency transaction losses are recognized in the Consolidated Statements of Operations as incurred.

Comprehensive Loss Policy [Policy Text Block]

Comprehensive Loss

Research and Development Expense, Policy [Policy Text Block]

Research and Development Costs

For the three months ended March 31, 2016 and 2015, the Company recognized research and development costs of $13.4 million and $19.6 million, respectively.

Significant Accounting Policies [Policy Text Block]

Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2015 Annual Report.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

XML 29 R20.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2016

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of March 31, 2016 and December 31, 2015 (in thousands):

Fair value measured at March 31, 2016

Quoted prices in active

Significant other

Significant

Fair value at

markets

observable inputs

unobservable inputs

March 31, 2016

(Level 1)

(Level 2)

(Level 3)

Derivative liability

14,457

Fair value measured at December 31, 2015

Quoted prices in active

Significant other

Significant

Fair value at

markets

observable inputs

unobservable inputs

December 31, 2015

(Level 1)

(Level 2)

(Level 3)

Derivative liability

27,982

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Warrant
	Liability
Balance - January 1, 2016	$	27,982
Change in fair value		(13,525)
Balance – March 31, 2016	$	14,457

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

Date of valuation	January 1, 2016			March 31, 2016
Strike price	$	3.49		$	2.38
Volatility (annual)		86.9	%		85.9	%
Risk-free rate		1.3	%		0.9	%
Contractual term (years)		3.1			3.0
Dividend yield (per share)		0	%		0	%

XML 30 R21.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment (Tables)

3 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment consist of the following at March 31, 2016 and December 31, 2015 (in thousands):

	March 31,		December 31,
	2016		2015
Leasehold improvements	$	69	$	69
Office furniture and equipment		25		25
Computer equipment and software		602		597
UK property acquisition, construction and estimated environmental liability		47,893		45,681

		48,589		46,373
Less: accumulated depreciation		(229)		(216)
	$	48,360	$	46,157

XML 31 R22.htm IDEA: XBRL DOCUMENT

Notes Payable (Tables)

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Interest Income and Interest Expense Disclosure [Table Text Block]

The following table shows the details of interest expenses related to 2014 Convertible Senior Notes for the three months ended March 31, 2016 and 2015, respectively (in thousands):

	For the three months ended
	March 31,
	2016		2015
Contractual interest	$	137	$	216
Amortization of debt issuance costs		70		105
Total interest expense on the convertible senior notes	$	207	$	321

Schedule of Debt [Table Text Block]

Notes payable consist of the following at March 31, 2016 and December 31, 2015 (in thousands):

	March 31,		December 31,
	2016		2015
Notes payable – current
12% unsecured originally due July 2011 - in dispute (1)	$	934	$	934
		934		934
Convertible notes payable, net - current
6% unsecured (2)		135		135
		135		135
Note payable
6% due on demand (3)		50		50
		50		50

Total notes payable, net	$	1,119	$	1,119

(3) This $0.050 million demand note as of March 31, 2016 is held by an officer of the Company. The holder has made no demand for payment, but reserves the right to make a demand at any time.

XML 32 R23.htm IDEA: XBRL DOCUMENT

Net Loss per Share Applicable to Common Stockholders (Tables)

3 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented (in thousands):

	For the three months ended
	March 31,
	2016		2015
Common stock options		1,551		1,551
Common stock warrants - equity treatment		26,876		15,830
Common stock warrants - liability treatment		15,839		12,500
Convertible notes and accrued interest		1,743		2,797
Potentially dilutive securities		46,009		32,678

XML 33 R24.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Deficit) (Tables)

3 Months Ended

Mar. 31, 2016

Stockholders' Equity Note [Abstract]

Schedule Of Warrant Activity [Table Text Block]

The following is a summary of warrant activity for the three months ended March 31, 2016 (in thousands, except per share data):

	Number of		Weighted Average
	Warrants		Exercise Price
Outstanding as of December 31, 2015		27,267,441	$	4.40
Warrants granted in a registered direct offering		12,058,825		3.04
Additional warrants owed to Cognate as part of reset		3,405,671		1.70
Warrants expired and cancelled		(16,791)		11.86
Outstanding as of March 31, 2016		42,715,146	$	3.53

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 34 R25.htm IDEA: XBRL DOCUMENT

Liquidity and Financial Condition (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net Cash Provided By (Used In) Operating Activities	$ (17,595)	$ (17,582)
Cash Equivalents, at Carrying Value	11,700
Current Assets Less Payables	44,300
Convertible Notes Payable Related Parties	6,400
Noncash Derivative Liability	44,300
Derivative Liability	14,500
Net Income (Loss) Attributable To Parent	(6,106)	$ (46,433)
Projected Potential Future Liability	$ 6,200

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 35 R26.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Summary of Significant Accounting Policies [Line Items]
Research and Development Expense	$ 13,440	$ 19,625
Accrued Environmental Loss Contingencies, Noncurrent	6,200
Site Contingency, Loss Exposure in Excess of Accrual, High Estimate	4,500
Site Contingency, Loss Exposure in Excess of Accrual, Low Estimate	32,000
Site Contingency, Loss Exposure in Excess of Accrual, Best Estimate	6,200
Foreign Currency Transaction Gain (Loss), Realized	(1,434)	$ 349
Foreign Currency Gain (Loss) [Member]
Summary of Significant Accounting Policies [Line Items]
Foreign Currency Transaction Gain (Loss), Realized	$ 500

XML 36 R27.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 14,457	$ 27,982
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 14,457	$ 27,982

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References + Details

XML 37 R28.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details 1) - Warrant Liability [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2016 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	$ 27,982
Change in fair value	(13,525)
Balance	$ 14,457

XML 38 R29.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details 2)	3 Months Ended
Fair Value Measurements (Details 2)	Mar. 31, 2016 $ / shares
Quantitative Information One [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price	$ 3.49
Volatility (annual)	86.90%
Risk-free rate	1.30%
Contractual term (years)	3 years 1 month 6 days
Dividend yield (per share)	0.00%
Quantitative Information Two [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price	$ 2.38
Volatility (annual)	85.90%
Risk-free rate	0.90%
Contractual term (years)	3 years
Dividend yield (per share)	0.00%

XML 39 R30.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment, Gross	$ 48,589	$ 46,373
Less: accumulated depreciation	(229)	(216)
Property, Plant and Equipment, Net	48,360	46,157
Leasehold improvements [Member]
Property, Plant and Equipment, Gross	69	69
Office furniture and equipment [Member]
Property, Plant and Equipment, Gross	25	25
Computer equipment and software [Member]
Property, Plant and Equipment, Gross	602	597
Property Acquisition and Construction [Member]
Property, Plant and Equipment, Gross	$ 47,893	$ 45,681

XML 40 R31.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Depreciation	$ 13,000	$ 3,000

XML 41 R32.htm IDEA: XBRL DOCUMENT

Notes Payable (Details) - USD ($) $ in Thousands	3 Months Ended
Notes Payable (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Contractual interest	$ 137	$ 216
Amortization of debt issuance costs	70	105
Total interest expense on the convertible senior notes	$ 207	$ 321

XML 42 R33.htm IDEA: XBRL DOCUMENT

Notes Payable (Details 1) - USD ($)
$ in Thousands

Mar. 31, 2016

Dec. 31, 2015

Debt Instrument [Line Items]

Notes payable - current

$ 934

Convertible notes payable, net - current

135

Notes payable

Total notes payable, net

1,119

Notes Payable Current, Unsecured, Issued One [Member]

Debt Instrument [Line Items]

Notes payable - current

^[1]

934

Convertible Notes Payable Current, Unsecured, Issued One [Member]

Debt Instrument [Line Items]

Convertible notes payable, net - current

^[2]

135

Note Payable [Member]

Debt Instrument [Line Items]

Notes payable

^[3]

$ 50

[1]	This $0.934 million note, which was originally due in July 2011 is currently under dispute with the creditor as to the validity of the note payable balance, which the Company believes has already been paid in full and is not outstanding.
[2]	This $0.135 million note as of March 31, 2016 consists of two separate 6% notes in the amounts of $0.110 million and $0.025 million. In regard to the $0.110 million note, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the $0.025 million note, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents.
[3]	This $0.050 million demand note as of March 31, 2016 is held by an officer of the Company. The holder has made no demand for payment, but reserves the right to make a demand at any time.

XML 43 R34.htm IDEA: XBRL DOCUMENT

Notes Payable (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Dec. 31, 2015

Debt Instrument [Line Items]

Notes Payable, Current, Total

$ 934

Convertible Debt, Current

135

Notes Payable, Noncurrent

Note One [Member]

Debt Instrument [Line Items]

Debt Conversion, Converted Instrument, Amount

110

Note Two [Member]

Debt Instrument [Line Items]

Debt Conversion, Converted Instrument, Amount

Mortgages [Member]

Debt Instrument [Line Items]

Interest Expense, Debt

400

$ 300

Write off of Deferred Debt Issuance Cost

$ 100

Second Mortgage [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Short-term Debt

$ 11,300

Second Mortgage [Member] | Mortgage Loans Due August 2016 [Member]

Debt Instrument [Line Items]

Deferred Finance Costs, Current, Net

300

Second Mortgage [Member] | Mortgage Loans Due November 2016 [Member]

Debt Instrument [Line Items]

Deferred Finance Costs, Current, Net

4,700

Senior Convertible Notes [Member]

Debt Instrument [Line Items]

Debt Conversion, Converted Instrument, Amount

$ 10,600

Debt Instrument, Convertible, Conversion Price

$ 6.60

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Escrow Deposit

$ 1,000

Deferred Offering Costs

400

Notes Payable Current, Unsecured, Issued One [Member]

Debt Instrument [Line Items]

Notes Payable, Current, Total

^[1]

934

Convertible Notes Payable Current, Unsecured, Issued One [Member]

Debt Instrument [Line Items]

Convertible Debt, Current

^[2]

$ 135

Convertible Notes Payable Current Unsecured Issued Two [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

6.00%

Notes Payable [Member]

Debt Instrument [Line Items]

Notes Payable, Noncurrent

$ 50

[1]

[2]

This $0.135 million note as of March 31, 2016 consists of two separate 6% notes in the amounts of $0.110 million and $0.025 million. In regard to the $0.110 million note, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the $0.025 million note, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents.

XML 44 R35.htm IDEA: XBRL DOCUMENT

Net Loss per Share Applicable to Common Stockholders (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	46,009	32,678
Common stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	1,551	1,551
Common stock warrants equity treatment [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	26,876	15,830
Common stock warrants liability treatment [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	15,839	12,500
Convertible notes and accrued interest [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	1,743	2,797

XML 45 R36.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Related Party Transaction [Line Items]
Share-based Compensation	$ 5.2	$ 6.4
Deferred Compensation Liability, Current and Noncurrent	$ 8.8
Common Stock Shares And Warrants Issued Favored Nation Provision Terms	On March 3, 2016, the Company entered into a financing under which it sold 5.9 million common shares and 12.1 million Series A, B and C warrants to unrelated investors on terms more favorable than the existing terms of Cognates shares. The sale of common shares had an effective price of $1.7, which triggered a most favored nation obligation which would result in an obligation to issue 6.0 million shares to Cognate. However, these shares have not been issued, and the Company is in active negotiations with Cognate seeking to modify these arrangements.
Cognate Bioservices [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	$ 6.4		$ 5.5
Payments to Acquire in Process Research and Development	$ 11.2	$ 14.7

XML 46 R37.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Deficit) (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2016 $ / shares shares
Shareholders Deficit [Line Items]
Number of Warrants, Outstanding as of December 31, 2015 \| shares	27,267,441
Number of Warrants, Warrants granted in a registered direct offering \| shares	12,058,825
Number Of Warrants - Additional warrants owed to Cognate as part of reset \| shares	3,405,671
Number of Warrants, Warrants expired and cancellation \| shares	(16,791)
Number of Warrants, Outstanding as of March 31, 2016 \| shares	42,715,146
Weighted Average Exercise Price - Outstanding \| $ / shares	$ 4.4
Weighted Average Exercise Price - Warrants granted in a registered direct offering \| $ / shares	3.04
Weighted Average Exercise Price - Additional warrants owed to Cognate as part of reset \| $ / shares	$ 1.70
Weighted Average Exercise Price - Warrants expired and cancellation \| $ / shares	11.86
Weighted Average Exercise Price - Outstanding as of March 31, 2016 \| $ / shares	$ 3.53

XML 47 R38.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Deficit) (Details Textual) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended
	Feb. 29, 2016	Mar. 31, 2016
Shareholders Deficit [Line Items]
Proceeds From Sale Of Available Securities Gross	$ 10.0
Proceeds from Sale of Available-for-sale Securities, Total	$ 9.2
Series A Warrants [Member]
Shareholders Deficit [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	5,882,353
Sale of Stock, Price Per Share	$ 1.70
Warrant Issued to Purchase Common Stock	2,941,177
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.25
Series B Warrants [Member]
Shareholders Deficit [Line Items]
Warrant Issued to Purchase Common Stock	5,882,353
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3.00
Series C Warrants [Member]
Shareholders Deficit [Line Items]
Warrant Issued to Purchase Common Stock	2,941,177
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.00
Warrants Expiration Period	5 years
Private Placement [Member]
Shareholders Deficit [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.125
Percentage Of Placement Fees On Aggregate Purchase Price Of Common Stock Sold		7.00%
Percentage Of Common Stock Warrants Issuable On Aggregate Number Of Shares Of Common Stock Sold		5.00%
Class Of Warrant Or Right Exercise Price Percentage On Public Offering Price		125.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		294,118

EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 87 186 1 true 40 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.nwbio.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.nwbio.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Sheet http://www.nwbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Statements 3 false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.nwbio.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.nwbio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 106 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://www.nwbio.com/role/CondensedConsolidatedStatementOfStockholdersEquityDeficit CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) Statements 6 false false R7.htm 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.nwbio.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 108 - Disclosure - Organization and Description of Business and Recent Developments Sheet http://www.nwbio.com/role/OrganizationAndDescriptionOfBusinessAndRecentDevelopments Organization and Description of Business and Recent Developments Notes 8 false false R9.htm 109 - Disclosure - Liquidity and Financial Condition Sheet http://www.nwbio.com/role/LiquidityAndFinancialCondition Liquidity and Financial Condition Notes 9 false false R10.htm 110 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.nwbio.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 111 - Disclosure - Fair Value Measurements Sheet http://www.nwbio.com/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 112 - Disclosure - Property, Plant and Equipment Sheet http://www.nwbio.com/role/PropertyPlantAndEquipment Property, Plant and Equipment Notes 12 false false R13.htm 113 - Disclosure - Notes Payable Notes http://www.nwbio.com/role/NotesPayable Notes Payable Notes 13 false false R14.htm 114 - Disclosure - Net Loss per Share Applicable to Common Stockholders Sheet http://www.nwbio.com/role/NetLossPerShareApplicableToCommonStockholders Net Loss per Share Applicable to Common Stockholders Notes 14 false false R15.htm 115 - Disclosure - Related Party Transactions Sheet http://www.nwbio.com/role/RelatedPartyTransactions Related Party Transactions Notes 15 false false R16.htm 116 - Disclosure - Stockholders' Equity (Deficit) Sheet http://www.nwbio.com/role/StockholdersEquityDeficit Stockholders' Equity (Deficit) Notes 16 false false R17.htm 117 - Disclosure - Contingencies Sheet http://www.nwbio.com/role/Contingencies Contingencies Notes 17 false false R18.htm 118 - Disclosure - Subsequent Events Sheet http://www.nwbio.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 119 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.nwbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.nwbio.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 120 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.nwbio.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.nwbio.com/role/FairValueMeasurements 20 false false R21.htm 121 - Disclosure - Property, Plant and Equipment (Tables) Sheet http://www.nwbio.com/role/PropertyPlantAndEquipmentTables Property, Plant and Equipment (Tables) Tables http://www.nwbio.com/role/PropertyPlantAndEquipment 21 false false R22.htm 122 - Disclosure - Notes Payable (Tables) Notes http://www.nwbio.com/role/NotesPayableTables Notes Payable (Tables) Tables http://www.nwbio.com/role/NotesPayable 22 false false R23.htm 123 - Disclosure - Net Loss per Share Applicable to Common Stockholders (Tables) Sheet http://www.nwbio.com/role/NetLossPerShareApplicableToCommonStockholdersTables Net Loss per Share Applicable to Common Stockholders (Tables) Tables http://www.nwbio.com/role/NetLossPerShareApplicableToCommonStockholders 23 false false R24.htm 124 - Disclosure - Stockholders' Equity (Deficit) (Tables) Sheet http://www.nwbio.com/role/StockholdersEquityDeficitTables Stockholders' Equity (Deficit) (Tables) Tables http://www.nwbio.com/role/StockholdersEquityDeficit 24 false false R25.htm 125 - Disclosure - Liquidity and Financial Condition (Details Textual) Sheet http://www.nwbio.com/role/LiquidityAndFinancialConditionDetailsTextual Liquidity and Financial Condition (Details Textual) Details http://www.nwbio.com/role/LiquidityAndFinancialCondition 25 false false R26.htm 126 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.nwbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) Details http://www.nwbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies 26 false false R27.htm 127 - Disclosure - Fair Value Measurements (Details) Sheet http://www.nwbio.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.nwbio.com/role/FairValueMeasurementsTables 27 false false R28.htm 128 - Disclosure - Fair Value Measurements (Details 1) Sheet http://www.nwbio.com/role/FairValueMeasurementsDetails1 Fair Value Measurements (Details 1) Details http://www.nwbio.com/role/FairValueMeasurementsTables 28 false false R29.htm 129 - Disclosure - Fair Value Measurements (Details 2) Sheet http://www.nwbio.com/role/FairValueMeasurementsDetails2 Fair Value Measurements (Details 2) Details http://www.nwbio.com/role/FairValueMeasurementsTables 29 false false R30.htm 130 - Disclosure - Property, Plant and Equipment (Details) Sheet http://www.nwbio.com/role/PropertyPlantAndEquipmentDetails Property, Plant and Equipment (Details) Details http://www.nwbio.com/role/PropertyPlantAndEquipmentTables 30 false false R31.htm 131 - Disclosure - Property, Plant and Equipment (Details Textual) Sheet http://www.nwbio.com/role/PropertyPlantAndEquipmentDetailsTextual Property, Plant and Equipment (Details Textual) Details http://www.nwbio.com/role/PropertyPlantAndEquipmentTables 31 false false R32.htm 132 - Disclosure - Notes Payable (Details) Notes http://www.nwbio.com/role/NotesPayableDetails Notes Payable (Details) Details http://www.nwbio.com/role/NotesPayableTables 32 false false R33.htm 133 - Disclosure - Notes Payable (Details 1) Notes http://www.nwbio.com/role/NotesPayableDetails1 Notes Payable (Details 1) Details http://www.nwbio.com/role/NotesPayableTables 33 false false R34.htm 134 - Disclosure - Notes Payable (Details Textual) Notes http://www.nwbio.com/role/NotesPayableDetailsTextual Notes Payable (Details Textual) Details http://www.nwbio.com/role/NotesPayableTables 34 false false R35.htm 135 - Disclosure - Net Loss per Share Applicable to Common Stockholders (Details) Sheet http://www.nwbio.com/role/NetLossPerShareApplicableToCommonStockholdersDetails Net Loss per Share Applicable to Common Stockholders (Details) Details http://www.nwbio.com/role/NetLossPerShareApplicableToCommonStockholdersTables 35 false false R36.htm 136 - Disclosure - Related Party Transactions (Details Textual) Sheet http://www.nwbio.com/role/RelatedPartyTransactionsDetailsTextual Related Party Transactions (Details Textual) Details http://www.nwbio.com/role/RelatedPartyTransactions 36 false false R37.htm 137 - Disclosure - Stockholders' Equity (Deficit) (Details) Sheet http://www.nwbio.com/role/StockholdersEquityDeficitDetails Stockholders' Equity (Deficit) (Details) Details http://www.nwbio.com/role/StockholdersEquityDeficitTables 37 false false R38.htm 138 - Disclosure - Stockholders' Equity (Deficit) (Details Textual) Sheet http://www.nwbio.com/role/StockholdersEquityDeficitDetailsTextual Stockholders' Equity (Deficit) (Details Textual) Details http://www.nwbio.com/role/StockholdersEquityDeficitTables 38 false false All Reports Book All Reports nwbo-20160331.xml nwbo-20160331.xsd nwbo-20160331_cal.xml nwbo-20160331_def.xml nwbo-20160331_lab.xml nwbo-20160331_pre.xml true true ZIP 54 0001144204-16-100593-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-16-100593-xbrl.zip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end